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ABSTRACT 
The cyclin-dependent kinase inhibitor p21WAF1/Cip1 (p21) is a cell-cycle checkpoint 
effector and inducer of senescence, regulated by p53. Yet, evidence suggests that, 
through a so-far obscure mechanism, p21 could also be oncogenic. We report that a 
subset of atypical cancerous cells strongly expressing p21 showed proliferation 
features. This occurred predominantly in p53-mutant human cancers suggesting p53-
independent upregulation of p21 selectively in more aggressive tumour cells. 
Multifaceted phenotypic and genomic analyses of p21-inducible, p53-null, cancerous 
and near-normal cellular models showed that after an initial senescence-like phase, a 
subpopulation of p21-expressing proliferating cells emerged, featuring increased 
genomic instability, aggressiveness and chemo-resistance. Mechanistically, sustained 
p21-accumulation inhibited mainly the CRL4CDT2 ubiquitin-ligase, leading to 
deregulated origin licensing and replication stress. Collectively, our data reveal tumour-
promoting ability of p21 through deregulation of DNA replication licensing machinery, 
an unorthodox role to be considered in cancer treatment, since p21 responds to various 
stimuli including some chemotherapy drugs. 
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Numerous proteins involved in key cellular processes display bimodality in cancer, 
acting either as tumour suppressors or oncoproteins (Supplementary Table S1). This 
phenomenon is commonly attributed to “cellular or environmental context”. 
Elucidating the mechanism(s) underlying such context-dependent duality is essential 
for rational design of cancer therapy. 
The cyclin-dependent kinase inhibitor (CDKI) p21WAF1/Cip1 (p21) is a pivotal 
downstream effector of the tumour-suppressor p53, mediating mainly G1-phase arrest 
and cellular senescence in response to various stimuli.1 Several studies suggest that p21 
can also manifest oncogenic properties (Supplementary Table S1). In some studies, 
p21’s oncogenic function was credited to unconventional cytoplasmic localization of 
p21 which inactivates pro-apoptotic proteins.2,3 Still, in most cases the underlying 
mechanism remains obscure. Notably, while p53 is frequently mutated in cancer,4 p21 
is rarely affected genetically.1,5 The latter would be logical if p21 operated exclusively 
within the p53 pathway. However, p21 is activated also by diverse p53-independent 
signals.1  
Replication licensing ensures that genome replication takes place once per cell 
cycle,6,7 due to the periodic expression of the replication licensing factors (RLFs) ORC, 
Cdt1 and Cdc6 that increase in late M to G1-phases and decrease in S/G2-phases.8 
Deregulation of the replication licensing process promotes genomic instability and 
tumorigenicity, mainly via unscheduled DNA re-replication.9,10,11,12 Aberrant 
expression of RLFs occurs in diverse malignancies.13,14 Here we present a 
pathophysiological mechanism demonstrating that protracted p21 expression, in a p53 
loss-of-function environment, causes deregulation of the replication licensing 
machinery, replication stress and genomic instability. 
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RESULTS 
A subset of atypical p21-expressing cells in advanced-stage tumours and 
preneoplastic lesions show signs of proliferation  
In an array of human tumours we observed an intriguing relationship between p21 
and the proliferation marker Ki67. While the anticipated mutually exclusive expression 
pattern of p21 and Ki67 was prevalent, consistent with p21’s growth-inhibitory 
properties, there was a number of atypical cancer cells co-expressing p21 and Ki67 (Fig. 
1a-c). Atypical cancer cells commonly point to adverse prognosis.15 Most of the 
carcinomas examined displayed p53 alterations.13,14,16 In preneoplastic lesions with p53 
aberrations we noticed a similar phenomenon (Fig. 1d).17 The unexpected co-
expression of p21 with Ki67 suggests either tolerance to high p21 levels, or selection 
under chronic p21 expression allowing for emergence of a subpopulation of p21-
positive cells which regained proliferative capacity and possibly acquired enhanced 
aggressiveness. 
 
p53-independent expression of p21 up-regulates replication licensing factors  
To address the impact of constitutive p21 expression in a p53-deficient context we 
employed two doxycycline-inducible (Tet-ON) p21 expressing cellular systems: one 
recapitulating the cancerous stage, based on Saos2, a p53-null human osteosarcoma cell 
line (Saos2 p21WAF1/Cip1 Tet-ON), and the other reflecting the precancerous stage by 
expressing the inducible module in the Li-Fraumeni-derived fibroblasts (MDAH041-
Li-Fraumemi p21WAF1/Cip1 Tet-ON)(Fig. 1e). The MDAH041 fibroblasts are p53-null 
human cells, considered “near”-normal, as they are reminiscent of normal diploid cells 
when p53 is restored, suggesting their downstream functions are largely intact.18 
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To avoid heterogeneity of p21 expression in bulk cell cultures, we isolated p21-
inducible clones that expressed p21 levels comparable to those observed in vivo and in 
cells exposed to genotoxic agents or p53-independent p21-inducing stimuli (like TGF-
β)1(Fig. 1e). Apart from monitoring cell proliferation, transcriptome and proteome 
landscapes were examined at distinct time-points (Fig. 1e) after p21 induction to 
identify candidate pathways/networks that could over time exercise an “oncogenic” 
effect (Supplementary Tables S2-S9). Representative high-throughput results were 
confirmed independently by quantitative real-time PCR and immunoblotting (Fig. 2a, 
Supplementary Fig. S1ai-ii). As expected,19 the p21-expressing clones reduced their 
growth rate and progressively acquired a senescent phenotype that peaked around day 
10 (Supplementary Fig. S1b, Video S1-S3). Consistent with such phenotypical 
changes, Gene-Ontology biological-process enrichment analyses revealed suppression 
of key “mitosis” factors (Supplementary Fig. S1a, Tables S2-S9). Unexpectedly and 
counter-intuitively, the proteome analysis revealed prominent up-regulation of the 
RLFs: Cdt1, Cdc6 and ORC (p=1.5 x 10-6); with Cdt1 protein increase being the earliest 
biochemical alteration among all measured parameters (Supplementary Tables S2-
S9). The increase of the RLFs was not accompanied by elevated mRNA, implying post-
transcriptional regulation (Fig. 2a). Similar results were observed in the Li-Fraumeni 
p21-inducible cells (Fig. 2b). Notably, p21, Cdt1 and Cdc6 share the same E3 ubiquitin 
ligase, CRL4CDT2.8,20 Continuous p21 expression might saturate its enzymatic activity 
leading to Cdt1 and Cdc6 accumulation (Fig. 2c). Consistently, SET8-methyltrasferase 
a known target of CRL4CDT2,21 was up-regulated after p21 induction (Fig. 2c). Shutting-
off p21, after a period of induction, led to an ubiquitylation-dependent decrease of Cdt1 
(Fig. 2d). Furthermore, transiently expressed mutant p21PCNA, that avoids p21 
degradation by CRL4CDT2, did not augment Cdt1 and Cdc6 abundance (Fig. 2e).20 Also, 
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induction of wild-type p21, but not the p21PCNA mutant, resulted in Cdt1 and Cdc6 
accumulation (Fig. 2f). Given that p21 has the strongest affinity amongst all PCNA 
interacting proteins (KD ~2.5 nM)22 these results strongly support a mechanism whereby 
excessive p21 saturates its own ubiquitin ligases allowing accumulation of other targets 
such as Cdt1 and Cdc6. The increase of G1-phase cells caused by p21 induction likely 
also contributed to the observed reduced RLF protein turnover, as RLFs are normally 
protected from degradation in G1 (Fig. 2g). Moreover, Cdc6 accumulation under 
conditions of blocked protein synthesis was not further enhanced upon proteasome 
inhibition, suggesting reduced protein turnover of Cdc6 (Fig. 2h), possibly also due to 
reduced activity of APCCdh1, another E3 ligase that targets Cdc6 for degradation.23 
Indeed, abundance of Cdh1/Fzr1, the substrate recognition and activating component 
of the APC was decreased (Fig. 2i). Down-regulation of Cdh1/Fzr1 contributes to high 
E2F1 levels (Fig. 2c, Supplementary Fig. S1ci-ii),24,25 thereby further boosting Cdt1 
expression.13 Enhanced Cdc6 stability was associated with Cdk2-mediated 
phosphorylation at Serine 54 (Cdc6-pS54) that protects Cdc6 from degradation (Fig. 
2h).23 Despite p21-mediated Cdk2 activity decrease (Supplementary Fig. S1ciii), 
reduction of Cdh1/Fzr1 appears to tilt the balance in favour of Cdc6 accumulation (total 
and Cdc6-pS54)(Fig. 2h). Notably, protein synthesis and proteasome inhibition did not 
restore Cdh1/Fzr1 protein levels implying regulation at the transcriptional level, a 
notion confirmed experimentally (Fig. 2i). 
Given that most clinical specimens with p21/Ki67-double-positive cells were p53-
deficient, we examined whether p53 impacts the ability of p21 to regulate the Cdt1 and 
Cdc6 levels, as previously suggested.26 Indeed, p21 expression in p53-defective and 
p53-wild-type (wt-p53) cell types resulted in increased (Figs. 2c;3a,d), and suppressed 
(Fig. 3b,c,e) RLF abundance, respectively. It was suggested that p53 shields the 
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organism from cells undergoing re-replication by triggering apoptosis.26 Consistently, 
after p21 induction wt-p53 HT1080 p21-IPTG-ON cells experienced massive 
apoptosis, accompanied by a dramatic decrease of Cdt1 and Cdc6 (Fig. 3e). Conversely, 
silencing of p53 suppressed apoptosis and allowed up-regulation of Cdt1 and Cdc6 
(Fig. 3e). Similar results were obtained upon p53 restoration in the Saos2 cellular 
system (Fig. 3c).27 Lastly, exposure to p53-independent p21-inducing stimuli such as 
TGF-β led to up-regulation of both RLFs (Fig. 3d). 
 
Expression of p21 in p53-null cells triggers replication-stress in a Cdt1/Cdc6-
dependent manner  
Re-replication is a form of replication stress driven mainly by inappropriate 
expression of RLFs6,8,9, leading to DNA damage and DNA damage response (DDR) 
activation.6,9 Following p21 induction in both, Saos2 and Li-Fraumeni p21 Tet-ON 
cellular systems, chromatin loading of the MCM2-7 helicase complex increased 
robustly indicating that Cdt1 and Cdc6 up-regulation is functional (Supplementary 
Fig. S1d). Flow cytometry analysis of cells double-stained for DNA content and DNA 
synthesis revealed a cell sub-population with DNA content greater than 4n, indicative 
of re-replication (Fig. 3f-h; Supplementary Video S4). Subsequently, DNA damage, 
assessed by the alkaline comet assay (total number of DNA lesions) and pulsed field 
gel electrophoresis (PFGE) was evident and accompanied by DDR, documented by 
H2AX phosphorylation (γH2AX) and increased 53BP1 foci formation (Fig. 4a-c,d-e; 
Supplementary Fig. S1ei-iv). Strikingly, re-replication, DNA damage DDR activation 
were Cdc6- and Cdt1-dependent, further suggesting that deregulated p21 causes 
replication stress associated with re-replication (Fig. 4b,c,d,e). Likewise, silencing of 
p21 alleviated DNA damage and DDR (Supplementary Fig. S1eiii,eiv and S2ai-iii). 
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DNA damage reduction was negligible upon dNTPs supplementation, in contrast to the 
impact of Cdt1 and Cdc6 silencing (Fig. 4d).28 Finally, re-replication and DNA damage 
were significantly reduced when the p21PCNA mutant was employed, consistent with our 
model that excess p21 acts by suppressing PCNA-dependent ubiquitylation of Cdt1 and 
Cdc6 (Fig. 2f,3h,4f; Supplementary Fig. S1ei,eii).8 
It seems paradoxical that p21 could trigger replication stress, given its role as a 
potent cell-cycle inhibitor. Nevertheless, DNA combing showed that replication fork 
progression did not cease, but its speed was reduced (Fig. 4g). In addition, replication 
fork asymmetry was observed, possibly related to the presence of DNA lesions 
impeding bi-directional fork movement (Fig. 4g). Consistently, multi-parameter flow 
cytometry analysis of γH2AX, DNA content and DNA synthesis showed that, 
following p21 induction, DNA damage accumulated mainly in cells incorporating EdU, 
whereas depletion of Cdc6 and Cdt1 profoundly suppressed the accumulation of DNA 
damage in S phase (Fig. 4h,i). Markedly, the cells expressing p21 demonstrated a focal 
PCNA pattern typical for early S phase (Supplementary Fig. S2b),29 suggesting that 
DNA damage occurs at a sensitive period when particularly active genes and early-
replication fragile sites are replicated.30 
 
p21-induced replication intermediates are processed by MUS81-EME1 and 
repaired by a Rad52-dependent mechanism  
To further characterize p21-induced replication stress, we examined single-
stranded DNA (ssDNA) formation, a common intermediate at replication-associated 
lesions. To this end, p21 expressing cells were incubated with BrdU under non-
denaturating conditions, allowing anti-BrdU staining to selectively visualize ssDNA 
regions.31 In situ analysis showed a strong correlation between the native BrdU staining 
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and p21 expression (Fig. 5a,b) that was also associated with an increased number of 
foci formed by the ssDNA-binding protein RPA (Fig. 5c). The ssDNA could occur 
either on the template or the newly synthesized (nascent) strand.32-34 BrdU staining was 
absent upon short BrdU pulses, suggesting that the source of ssDNA is the template 
strand (Supplementary Fig. S2c). 
Next, we inspected replication intermediates in vivo by an established electron 
microscopy method.35 Compared to wt-p53 U2OS cell line,36 in unperturbed Saos2 
cells we found pronounced accumulation of the so-called reversed forks (Fig. 5di), 
four-way DNA junctions that have been proposed to limit the amount of exposed 
ssDNA and thereby possibly mitigate the detrimental impact of gross replication 
stress.36,37 Expression of p21 in the Saos2 cell model led to a marked accumulation of 
small replication bubbles (Fig. 5dii), decreased fork reversal and enhanced 
accumulation of ssDNA stretches at replication forks, with most small bubbles showing 
one side entirely single-stranded (hemireplicated)(Fig. 5di,5diii). Overall, these data 
are consistent with the notion that p21 expression in p53-defective cancer cells 
deregulates origin firing, leading to accumulation of ssDNA and increased replication 
stress. 
Replication intermediates need to be resolved for replication to restart. After long 
periods of replication inhibition, DSBs generated by the structure-specific resolvase 
complex of MUS81-EME1 are required for replication restart.32,38 We hypothesized 
that sustained p21 expression may phenocopy the latter state. Indeed, MUS81-EME1 
depletion caused a significant DNA damage decrease, inflicted by p21 expression, as 
well as reduction of EdU-positive cells harbouring signs of DNA damage (Fig. 5e-g; 
Supplementary Fig. S2di-ii). MUS81-EME1 is considered a central player in 
oncogene-induced DNA damage response,39,40 promoting homologous recombination 
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(HR)-mediated repair of inactivated (collapsed) forks.32 Surprisingly, we noticed that 
silencing of the HR recombinase Rad51 resulted in decreased γH2AX levels (Fig. 5h). 
This finding implies a negative control over an alternative, Rad51-indepenent, repair 
process. Rad51 seems to exert such an effect preventing Rad52-dependent DNA 
repair.41 Indeed, suppression of Rad52 was followed by increased γH2AX and cell 
death in both p21-induced models (Fig. 5i,j,k), suggesting that Rad52 guided the repair 
process. Rad52 is possibly involved in error-prone microhomology-mediated repair 
pathways challenging genomic stability.42,43 Interestingly, Rad51 levels were reduced 
upon p21 induction (Fig. 5h; Supplementary Fig. S2diii). Rad51 is in short supply and 
under stressful conditions, such as hypoxia, Rad51 is repressed by E2F4/p130 
complexes. Such complexes are recruited by p21 to mediate gene repression.44 In 
accordance, the promoter of Rad51 was occupied by E2F4 (Fig. 5l), providing an 
explanation why Rad52 is chosen for repair in this setting. 
 
Deregulated Cdt1 and Cdc6 link p53-independent p21 induction with senescence 
Sustained p53-independent p21 expression triggered senescence, a well established 
antitumor barrier, in a Cdt1- and Cdc6-dependent manner (Fig. 6a,b).14,45 Consistently, 
no signs of senescence were observed when the p21PCNA inducible mutant was 
employed or p21 was silenced (Fig 6c, Supplementary Fig. S2ai-iii). As p73, the p53 
homologue, responds to DDR signaling,46 we asked whether p73 could operate 
downstream in the emerging p21–RLFs–DDR–signalling route. Indeed, p73 proved to 
be required for the p21-Cdt1/Cdc6-induced senescence (Fig. 6d,e). 
According to the oncogene-induced DNA damage concept for cancer development, 
the DDR-mediated anti-tumour barriers are breached at some point in tumours that 
progress, accompanied by genomic instability.12 If this concept is applicable for chronic 
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p53-independent p21 induction, then in due time the p21 expressing cells could bypass 
the senescence barrier generating more aggressive outgrowing clones. Cdc6 
overexpression per se could contribute to senescence bypass by repressing the 
INK4/ARF locus,47 encoding p16INK4A, an indispensible factor of irreversible 
senescence.48 Indeed, p21 activation led to down-regulation of both INK4/ARF 
products, p16INK4A and p14ARF, undermining the durability of p21-mediated senescence 
(Fig. 6f,g). 
 
Senescence bypass, genomic instability and enhanced aggressiveness under 
protracted p21 expression  
After 10 days of p21 induction in p53-deficient models the senescent phenotype 
gradually declined and a sub-population of proliferating p21-positive cells emerged 
(Fig. 7a-e; Supplementary Video S5). Likewise the mutually exclusive expression 
pattern of cyclin A-an established late S/G2 marker-49,50 and p21 was reduced and 
replaced by a p21/cyclin A double-positive cell sub-population (Fig. 7f). It appears that 
a fraction of p21 expressing cells evaded arrest/senescence, re-entering the cell cycle 
(“escaped cells”). Cdk2 activity and its stimulatory phosphorylation (p-T160) were 
concomitantly restored (Fig. 7g; Supplementary Fig. S2ei). Notably, p21 expression 
in the “escaped” cells was similar to, or even higher than, that observed in the initial 
phase of p21 induction, excluding the possibility that low p21 stoichiometric 
concentrations drive proliferation (Fig. 7g; Supplementary Fig. S2eii-iii).1 The 
“escaped” cells showed a dramatic reduction of p73 expression (Fig. 7g,h). There was 
no evidence of genetic or epigenetic inactivation of the p73 locus but instead 
downregulation of EGR1, the main transcriptional activator of TP73 (Supplementary 
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Figs. S2f,S3-5).51 The nuclei in most “escaped” cells were larger than those in the 
cycling control cells (Fig. 7i, Supplementary Video S5), a feature noticed also in vivo 
(Fig. 1,7j; Supplementary Fig. S2g). Noticeably, in vivo, the cells displaying 
Ki67/p21 coexpression were also Cdc6 and/or Cdt1 positive (Fig 7j; Supplementary 
Fig. S2g). DNA damage was also reduced in the “escaped” cells implying that a repair 
process took place (Fig. 7k). The involvement of the MUS81-EME1 - Rad52 repair 
route (Fig. 5e-k) and the increased presence of micronuclei (Fig. 8a) that are considered 
surrogate markers of chromosomal instability, defective DDR and repair,52 indicated, 
that such repair was error-prone. To gain a genome-wide view of this emerging scenario 
we performed aCGH, deep sequencing and M/FISH/SKY comparing the “escaped” and 
the un-induced cells (Fig. 8; Supplementary Fig. S4-6, Tables S10-S12). 
Cumulatively, the results from six independent biological replicates employing all three 
experimental procedures showed that the genomic landscape of the “escaped” cells 
acquired chromosomal aberrations, in the form of gains and losses (Fig. 8b,c; 
Supplementary Fig. S4a-c,S5,S6, Tables S10-S12), as well as novel translocations 
(Fig. 8d,e,f; Supplementary Fig. S4c, Table S13-S15). Notably, high frequency of 
microhomologies (≥ 2 nucleotides)42 was identified adjacent to the novel breakpoints 
in both systems, favoring a role of microhomology-mediated repair in p21-driven 
genomic instability (Figure 8d,e; Supplementary Fig. S7, Table S16). Interestingly 
among the genetic lesions found were alterations reminiscent of chromoanasynthesis or 
chromothripsis (Fig. 8b,c; Supplementary Table S10,S11).53 Given that the 
multifaceted chromosomal assessment showed concordant results (Fig. 8d-g; 
Supplementary Fig. S4-S6) and each experimental procedure took place at different 
time periods, we propose that p21 may steer a “deterministic” set of genetic events that 
may play a role in the behavior of the “escaped” cells. In line with this notion the 
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transcriptome of the “escaped” cells (Supplementary Fig. S3,S8) demonstrated a 
specific non-random correlation with the genomic alterations found in these cells 
(p<2.2*10-16 for the Saos2 and p=0.0013 for the Li-Fraumeni cells). Deregulation of 
the replication licensing machinery was the earliest biochemical event observed upon 
p21 induction, further suggesting that genomic instability “drove” the alterations in 
transcriptome landscapes of the “escaped” cells. While p21 is not a transcription factor 
it can modulate transcription in certain cases.54 However, the fact that only 42 (7.6%) 
of the 553 genes and 538 (15%) of the 3507 genes found differentially expressed in the 
“escaped” Saos2 and Li-Fraumeni p21 Tet-ON cells, respectively, were detected in 
earlier time-points makes the latter scenario of more ‘direct’ transcriptional effects of 
p21 most unlikely (Supplementary Fig. S8). 
Importantly the “escaped” clones demonstrated enhanced anchorage-independent 
growth and were more invasive (Fig. 8h,i,l). Furthermore, they tolerated treatment with 
genotoxic drugs doxorubicin and cisplatin much more efficiently, yet showed no 
significant difference in the response to taxol, a microtubule polymer stabilizer. The 
enhanced resistance to doxorubicin and cisplatin persisted even when p21 was switched 
off in the “escaped” cells for 10 days, documenting that this feature was a durable 
consequence, independent of any potential p21-mediated transient transcriptional effect 
(Fig. 8j,m). This chemoresistance effect was absent when p21 was silenced very early 
after p21 induction (Supplementary Fig. S2ai-iii). A number of the transcriptionally 
altered genes connected with aggressive behaviour could help interpret the acquired 
aggressive phenotypic features (Supplementary Fig. S3d,e, Table S17-S22). 
Furthermore, assessments of tumor-sphere formation and anchorage independent 
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growth indicated that the “escaped” populations are enriched in cells with “stemness”-
like features (Fig. 8k, Supplementary Fig. S3d). 
 
18 
 
DISCUSSION  
The present dataset demonstrates an unexpected p21-mediated oncogenic 
mechanism that is distinct from that reported for leukemia stem-cells.55 It also explains 
why p21 is only transiently expressed during induction of senescence48,56 and how p53 
inactivation can tip the balance towards the p21’s oncogenic function.  
When free from influence of wt-p53, p21 induced by p53-independent signals 
causes deregulation of the replication licensing machinery triggering replication stress. 
We provide evidence that continuous production of p21 suppresses its degradation 
module, CRL4CDT2, possibly by oversaturating it as p21 has the strongest PCNA-
binding affinity (Supplementary Fig. 8c),22 thereby leaving their other targets, 
including Cdt1, Cdc6 and E2F1 unabated to perform their functions (Supplementary 
Fig. 8c). Since Cdt1 expression is positively regulated by E2F1,13 such feed-forward 
mechanism could further boost Cdt1 expression (Supplementary Fig. 8c). Although 
CRL4CDT2 seems to be the key player in this process, SCFSkp2 which also targets p21 
and Cdt1 may also contribute.1,22,57  
By up-regulating the pivotal replication licensing factors Cdt1 and Cdc6, the cells 
expressing p21 acquire the capacity to re-replicate (or “endo-reduplicate)”, a 
phenomenon that we now explain mechanistically.58 We show that p21-mediated 
genome re-replication eventually drives a chromosome-destabilizing process giving 
rise to descendant cells with more aggressive cancerous features (Supplementary Fig. 
8c). Re-replication is a form of replication stress that leads to replication fork stalling, 
collapse, DNA damage and eventually genomic instability.8,9,59 Within this context, the 
p53 checkpoint was shown to limit re-replication, via eliminating re-replicating cells 
by apoptosis (Fig. 3b).26 The fact that the turn-over of p21, Cdt1 and Cdc6 is controlled 
by the same E3-ubiquitin ligase, CRL4CDT2, underscores the significance of p53 whose 
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inactivation abolishes a cell-protective mechanism. Given that p21 mutations are 
extremely rare events in cancer,1,5 it is apparent that human cancers with mutant p53 
are at risk of suffering additional deleterious, tumour heterogeneity-promoting genetic 
alterations by protracted operation of p21, induced through p53-independent signals 
(Supplementary Fig. 1eiii-iv).1  
The ensuing involvement of MUS81-EME1 and the recombinase Rad52 point 
towards a replication-based error-prone DNA repair process.39,40 Reduction of Rad51 
elicits a switch from high-fidelity homologous recombination to a lower-fidelity repair 
process mediated by Rad52 that requires much less homology (micro-
homology)(Supplementary Fig. 8c).41,42,60 The altered genomic landscape and the high 
frequency of micro-homologies found within and adjacent to the mapped breakpoints 
supports the latter scenario (Supplementary Fig. S4-7). Among the chromosomal 
aberrations observed, chromoanasynthesis results from replicative template-switching 
events (Fig. 8b,c).61 However, chromothripsis, another complex chromosomal 
rearrangement pattern noticed here (Fig. 8b,c), is considered to be the outcome of 
NHEJ,62 implying that other repair pathways, possibly non-replicative ones, may also 
contribute to the p21–driven genomic instability.  
A question that always emerges is whether genomic alterations represent a 
passenger or a driver event. The strong correlation between the transcriptome and 
genome changes supports the latter possibility. Among the transcripts found deranged 
were growth factors and metalloproteinases that could account for the aggressive 
behavior of the “escaped” cells (Supplementary Fig. S3; Table S17-S22). Notably, 
ID1 shown to antagonize the suppressive effects of p16INK4A and p21,63 was up-
regulated in the “escaped” cells (Supplementary Fig. S3).  
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Collectively, p21-driven genomic instability constitutes part of a selection 
trajectory to promote survival and long-term cancer evolution,64 as illustrated mainly 
by the increased aggressiveness and resistance of the “escaped” cells to genotoxic 
agents. This tumour evolutionary scenario involves a combination of p53 defects 
permissible for passage through a reversible senescence phase (Fig. 6f,g)48,57 that 
“conceals” an underlying replication stress-based/error-prone repair route that over 
time ensures that the “fittest and more adapted cancer cells” emerge.10 Our results 
highlight the “dark side” of p21 that should be taken into consideration when designing 
therapeutic strategies, particularly for p53-deficient tumours, as agents used in clinical 
oncology, such as dexamethazone, can induce p21 in a p53-independent manner with 
potential detrimental effects to patients.65 
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METHODS 
Methods and any associated references are available in the online version of the paper. 
 
Acknowledgements. We would like to thank Drs A. Kotsinas, K. Evangelou, T. 
Liloglou and A. Georgakilas for their valuable support to this work. We would like to 
thank Prof A. Dutta for kindly providing the vectors with wt and PIP mutated domain 
of p21WAF1/Cip1, Dr G. Blandino for the H1299 p21WAF1/Cip1–Ponesterone-ON cells and 
Dr Z. Lygerou for the secondary antibodies employed in the IF analyses. We thank Mr. 
Roger Allsopp, Mr. Derek Coates, the Wessex Cancer Trust and Medical Research, 
U.K., and the University of Southampton “Annual Adventures in Research” fund for 
their support of the proteomics infrastructure and its use for this study. We are also 
indebted to the PRIDE team for the proteomics data processing−repository assistance. 
This work received funding from the European Union’s Seventh Framework 
Programme (project INsPiRE), the Greek GSRT program of Excellence II (Aristeia II) 
the Hellenic Association for Molecular Cancer Research (HAMCR), and partial 
funding from the Research Institute for the Study of Genetic and Malignant Diseases in 
Childhood, “Aghia Sophia”  Childrens Hospital, Athens, Greece, the Danish National 
Research Foundation (Center of excellence project CARD), the Lundbeck Foundation 
and the Danish Council for Independent Research. 
 
AUTHOR CONTRIBUTIONS 
PG, KV and DW: cell culture and manipulations, siRNA/plasmid/viral 
transfections/transductions/infections, immunoblots, cell growth, RT-PCR, ChIP, 
Comet, IHC and IF assays. DW and CSS: PFGE analysis. AMM and JB: DNA fiber 
spreading assay. AKA, RZ, SH, ML: electron microscopy (EM) and cell culture for 
22 
 
EM. EJH and JJB: FACS analyses. BC, AI and AN: video laps analyses. DK: MTT, 
soft agar, invasion and kinase assays. FMR and SG: molecular cytogenetic analyses. 
AP, AK and DT: deep and RNA sequencing. MT and EK: aCGH analyses. KV, SDG 
and PT: proteomic analysis. IR: Data analysis and cell line production. KV and AP: 
transcriptomic and bioinformatic analyses. JJB, CSS, AN and JB: data analysis and 
interpretation, and assistance in manuscript preparation. VGG: experimental design, 
guidance, manuscript preparation and writing. 
 
COMPETING FINANCIAL INTERESTS  
The authors declare no competing financial interests. 
 
In the memory of Ioannis Terrovitis 
23 
 
REFERENCES  
1. Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat 
Rev Cancer 9, 400-414 (2009).  
2. Roninson, I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): 
association with cell senescence and tumour-promoting activities of stromal fibroblasts. 
Cancer Lett 179, 1-14 (2002). 
3. Pateras, I.S., Apostolopoulou, K., Niforou, K., Kotsinas, A. & Gorgoulis, V.G. 
p57KIP2: "Kip"ing the cell under control. Mol Cancer Res 7, 1902-1919 (2009).  
4. Rivlin, N., Brosh, R., Oren, M. & Rotter, V. Mutations in the p53 tumor suppressor 
gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2, 466-
474 (2011).  
5. Warfel, N.A. & El-Deiry, W.S. p21WAF1 and tumourigenesis: 20 years after. Curr 
Opin Oncol 25, 52-58 (2013).  
6. Abbas, T., Keaton, M.A. & Dutta, A. Genomic instability in cancer. Cold Spring 
Harb Perspect Biol 5, a012914 (2013).  
7. Blow, J.J. & Dutta, A. Preventing re-replication of chromosomal DNA. Nat Rev Mol 
Cell Biol. 6, 476-486 (2005). 
8. Petrakis, T.G. et al. Exploring and exploiting the systemic effects of deregulated 
replication licensing. Semin Cancer Biol pii: S1044-579X(15)30003-1 (2015) [Epub 
ahead of print].   
9. Blow, J.J. & Gillespie, P.J. Replication licensing and cancer--a fatal entanglement? 
Nat Rev Cancer 8, 799-806 (2008).  
24 
 
10. Negrini, S., Gorgoulis, V.G. & Halazonetis, T.D. Genomic instability-an evolving 
hallmark of cancer. Nat Rev Mol Cell Biol 11, 220-228 (2010).  
11. Halazonetis, T.D., Gorgoulis, V.G. & Bartek, J. An oncogene-induced DNA 
damage model for cancer development. Science 319, 1352-1355 (2008).  
12. Sideridou, M. et al. Cdc6 expression represses E-cadherin transcription and 
activates adjacent replication origins. J Cell Biol 195, 1123-1140 (2011). 
13. Karakaidos, P. et al. Overexpression of the replication licensing regulators hCdt1 
and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect 
with mutant p53 on tumor growth and chromosomal instability-evidence of E2F-1 
transcriptional control over hCdt1. Am J Pathol 165, 1351-1365 (2004). 
14. Liontos, M. et al. Deregulated overexpression of hCdt1 and hCdc6 promotes 
malignant behavior. Cancer Res 67, 10899-10909 (2007). 
15. Rosai, J.R. & Ackerman's Surgical Pathology. Elsevier, London, UK (2011). 
16. Velimezi, G. et al. Functional interplay between the DNA-damage-response kinase 
ATM and ARF tumour suppressor protein in human cancer. Nat Cell Biol 15, 967-977 
(2013).  
17. Cooks, T. et al. Mutant p53 prolongs NF-κB activation and promotes chronic 
inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634-646 
(2013). 
18. Agarwal, M.L., Agarwal, A., Taylor, W.R. & Stark, G.R. p53 controls both the 
G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human 
fibroblasts. Proc Natl Acad Sci U S A 92, 8493-8497 (1995). 
25 
 
19. Bates, S., Ryan, K.M., Phillips, A.C. & Vousden, K.H. Cell cycle arrest and DNA 
endoreduplication following p21Waf1/Cip1 expression. Oncogene 17, 1691-1703 
(1998). 
20. Havens, C.G. & Walter, J.C. Mechanism of CRL4(Cdt2), a PCNA-dependent E3 
ubiquitin ligase. Genes Dev 25, 1568-1582 (2011).  
21. Jørgensen, S. et al. SET8 is degraded via PCNA-coupled CRL4(CDT2) 
ubiquitylation in S phase and after UV irradiation. J Cell Biol 192, 43-54 (2011).  
22. Gibbs, E. et al. The influence of the proliferating cell nuclear antigen-interacting 
domain of p21(CIP1) on DNA synthesis catalyzed by the human and Saccharomyces 
cerevisiae polymerase delta holoenzymes. J Biol Chem 272, 2373-2381 (1997).  
23. Duursma, A. & Agami, R. p53-Dependent regulation of Cdc6 protein stability 
controls cellular proliferation. Mol Cell Biol 25, 6937-6947 (2005). 
24. Peart, M.J. et al. APC/C(Cdc20) targets E2F1 for degradation in prometaphase. Cell 
Cycle 9, 3956-3964 (2010). 
25. Budhavarapu, V.N. et al, Regulation of E2F1 by APC/C Cdh1 via K11 linkage-
specific ubiquitin chain formation. Cell Cycle 11, 2030-2038 (2012). 
26. Vaziri, C. et al. A p53-dependent checkpoint pathway prevents rereplication. Mol 
Cell 11, 997-1008 (2003). 
27. Gorgoulis, V.G. et al. p53 activates ICAM-1 (CD54) expression in an NF-kappaB-
independent manner. EMBO J 22, 1567-1578 (2003). 
28. Bester, A.C. et al. Nucleotide deficiency promotes genomic instability in early 
stages of cancer development. Cell Apr 145, 435-446 (2011). 
26 
 
29. Essers, J. et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell 
Biol 25, 9350-9359 (2005). 
30. Barlow, J.H. et al. Identification of early replicating fragile sites that contribute to 
genome instability. Cell 152, 620-632 (2013).  
31. Beck, H. et al. Regulators of cyclin-dependent kinases are crucial for maintaining 
genome integrity in S phase. J Cell Biol 188, 629-638 (2010). 
32. Petermann, E. & Helleday, T. Pathways of mammalian replication fork restart. Nat 
Rev Mol Cell Biol 11, 683-687 (2010).  
33. Neelsen, K.J. et al. Deregulated origin licensing leads to chromosomal breaks by 
rereplication of a gapped DNA template. Genes Dev 27, 2537-2542 (2013).  
34. Couch, F.B. et al. ATR phosphorylates SMARCAL1 to prevent replication fork 
collapse. Genes Dev 27, 1610-1623 (2013). 
35. Neelsen, K.J. et al. Visualization and interpretation of eukaryotic DNA replication 
intermediates in vivo by electron microscopy. Methods Mol Biol 1094, 177-208 (2014). 
36. Zellweger, R. et al. Rad51-mediated replication fork reversal is a global response 
to genotoxic treatments in human cells. J Cell Biol 208, 563-579 (2015). 
37. Neelsen, K.J. & Lopes, M. Replication fork reversal in eukaryotes: from dead end 
to dynamic response. Nat Rev Mol Cell Biol 16, 207-220 (2015).  
38. Hanada, K. et al. The structure-specific endonuclease Mus81 contributes to 
replication restart by generating double-strand DNA breaks. Nat Struct Mol Biol 14, 
1096-1104 (2007). 
39. Neelsen, K.J., Zanini, I.M., Herrador, R. & Lopes, M. Oncogenes induce genotoxic 
stress by mitotic processing of unusual replication intermediates. J Cell Biol 200, 699-
708 (2013).  
27 
 
40. Murfuni, I. et al. The WRN and MUS81 proteins limit cell death and genome 
instability following oncogene activation. Oncogene 32, 610-620 (2013).  
41. Wu, Y., Kantake, N., Sugiyama, T. & Kowalczykowski, S.C. Rad51 protein 
controls Rad52-mediated DNA annealing. J Biol Chem 283, 14883-14892 (2008).  
42. Ottaviani, D., LeCain, M. & Sheer, D. The role of microhomology in genomic 
structural variation. Trends Genet 30, 85-94 (2014).  
43. Iraqui, I. et al. Recovery of arrested replication forks by homologous recombination 
is error-prone. PLoS Genet 8, e1002976 (2012).  
44. Benson, E.K. et al. p53-dependent gene repression through p21 is mediated by 
recruitment of E2F4 repression complexes. Oncogene 33, 3959-3969 (2014)  
45. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier 
imposed by DNA damage checkpoints. Nature 444, 633-637 (2006). 
46. Liontos, M. et al. Modulation of the E2F1-driven cancer cell fate by the DNA 
damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J 
Pathol 175, 376-391 (2009).  
47. Gonzalez, S. et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF 
locus. Nature 440, 702-706 (2006). 
48. Beauséjour, C.M. et al. Reversal of human cellular senescence: roles of the p53 and 
p16 pathways. EMBO J 22, 4212-4222 (2003).  
49. Woo, R.A. & Poon, R.Y. Cyclin-dependent kinases and S phase control in 
mammalian cells. Cell Cycle 2, 316-324 (2003). 
28 
 
50. Pines, J. & Hunter, T. Human cyclins A and B1 are differentially located in the cell 
and undergo cell cycle-dependent nuclear transport. J Cell Biol 115, 1-17 (1991). 
51. Yu, J. et al. A network of p73, p53 and Egr1 is required for efficient apoptosis in 
tumor cells. Cell Death Differ 14, 436-446 (2007). 
52. Terradas, M., Martín, M., Tusell, L. & Genescà, A. DNA lesions sequestered in 
micronuclei induce a local defective-damage response. DNA Repair (Amst). 8, 1225-
1234 (2009). 
53. Holland, A.J. & Cleveland, D.W. Chromoanagenesis and cancer: mechanisms and 
consequences of localized, complex chromosomal rearrangements. Nat Med 18, 1630-
1638 (2012).  
54. Perkins, N.D. et al. Regulation of NF-kappaB by cyclin-dependent kinases 
associated with the p300 coactivator. Science 275, 523-527 (1997). 
55. Viale, A. et al. Cell-cycle restriction limits DNA damage and maintains self-
renewal of leukaemia stem cells. Nature 457, 51-56 (2009). 
56. Shay, J.W. & Roninson, I.B. Hallmarks of senescence in carcinogenesis and cancer 
therapy. Oncogene 23, 2919-2933 (2004). 
57. Nishitani, H. et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target 
human Cdt1 for proteolysis. EMBO J 25, 1126-1136 (2006). 
58. Niculescu, A.B. et al. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M 
cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in 
preventing endoreduplication. Mol Cell Biol. 18, 629-643 (1998). 
29 
 
59. Porter, A.C. Preventing DNA over-replication: a Cdk perspective. Cell Div 3, 3 doi: 
10.1186/1747-1028-3-3 (2008).  
60. Hastings, P.J., Ira, G. & Lupski, J.R. A microhomology-mediated break-induced 
replication model for the origin of human copy number variation. PLoS Genet 5, 
e1000327 (2009).  
61. Zhang, C.Z., Leibowitz, M.L. & Pellman, D. Chromothripsis and beyond: rapid 
genome evolution from complex chromosomal rearrangements. Genes Dev 27, 2513-
2530 (2013). 
62. Stephens, P.J. et al. Massive genomic rearrangement acquired in a single 
catastrophic event during cancer development. Cell 144, 27-40 (2011).  
63. Sikder, H.A., Devlin, M.K., Dunlap, S., Ryu, B. & Alani, R.M. Id proteins in cell 
growth and tumorigenesis. Cancer Cell 3, 525-530 (2003). 
64. Burrell, R.A., McGranahan, N., Bartek, J. & Swanton, C. The causes and 
consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345, 
(2013). 
65. Cha, H.H. et al. Glucocorticoids stimulate p21 gene expression by targeting 
multiple transcriptional elements within a steroid responsive region of the 
p21waf1/cip1 promoter in rat hepatoma cells. J Biol Chem 273, 1998-2007 (1998). 
66. Georgakopoulou, E.A. et al. Specific lipofuscin staining as a novel biomarker to 
detect replicative and stress-induced senescence. A method applicable in cryo-
preserved and archival tissues. Aging (Albany NY) 5, 37-50 (2013). 
 
30 
 
Figure legends 
Figure 1. The p21 and Ki67 are co-expressed in a subset of atypical cells of high 
grade/poorly differentiated, advanced human carcinomas and precancerous 
lesions. Serial-section immunohistochemical (IHC) analysis and double 
immunofluorescent (IF) analysis showed co-expression of p21 and the mitotic marker 
Ki67 in a subset of large cancer cells with giant nuclei in (a) head and neck squamous 
cell carcinomas, (b) lung squamous cell carcinomas (inset depicts in higher 
magnification, a large atypical cell with p21/Ki67 co-expression), (c) urothelial 
carcinomas and (d) colon precancerous lesions (dysplasia-associated lesions or masses 
– DALMs), obtained from patients with ulcerative colitis, that are known to exhibit 
early p53 aberrations.17  (e) Cellular models used to recapitulate the in vivo 
observations. Timeline of p21 induction in Li-Fraumeni p21WAF1/Cip1 Tet-ON and Saos2 
p21WAF1/Cip1 Tet-ON cells, showing time points where main biochemical and 
phenotypical events occur. IHC and IF: Black and white thin arrows denote p21 and 
Ki67 co-expressing cells, respectively; IF: white and yellow thick arrows depict cells 
with mutual exclusive p21 and Ki67 expression, respectively. Scale bars in IHC panels: 
50 µm, IF panels: 50 µm. Uncropped images of blots in Supplementary Fig. S9.  
 
Figure 2. Prolonged stimulation of p21 up-regulates and stabilizes the Replication 
Licensing Factors (RLFs), Cdc6 and Cdt1, at the protein level. (a) Upper panel: 
Heat-maps of transcriptomic and proteomic analyses, at days 2 and 4, after p21 
induction in Saos2 p21WAF1/Cip1 Tet-ON cells. Set of significant overexpressed and 
underexpressed genes are shown, respectively. Lower panel: Schematic representative 
significant genes that are up-regulated and down-regulated, along with their 
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biochemical function, at day 4 of p21WAF1/Cip1 induction. Data derived from 3 biological 
replicates (transcriptomics) and 2 biological replicates (proteomics), respectively, see 
methods. (b) p21 induction in Li-Fraumeni p21WAF1/Cip1 Tet-ON cells leads to Cdt1 and 
Cdc6 upregulation only at protein level. Lower panel: Real-time RT-PCR performed at 
depicted time points showing no changes in transcriptional levels of same factors (p = 
NS, ANOVA, error bars indicate mean +/- SDs, n=3 experiments). (c) Cdt1 stabilization 
possibly via suppression of CRL4CDT2 ubiquitin ligase complex due to overabundance 
of p21 (see text for details). (d) Ubiquitination-dependent decrease of Cdt1 levels upon 
switching-off p21. Doxycycline-induced Saos2 p21WAF1/Cip1 Tet-ON cells were 
subsequently shut-off for the indicated time points and treated also with 30µM MG132 
(* p < 0.0001, ANOVA, error bars indicate mean +/- SDs, n=3 blots). (e) Saos2 cells 
were transfected with wild-type p21WAF1/Cip1 and a specific p21WAF1/Cip1 mutant 
[p21PCNA: harboring Q144, M147, F150 substitutions to A in its PCNA-interacting-
protein (PIP) degron motif- see panel below] abrogating its interaction with PCNA. 
(Empty vector: pMSCV, p21WAF1: pMSCV-p21WAF1/Cip1, p21PCNA: pMSCV-p21PCNA). 
(f) Induction of p21PCNA abrogated upregulation of Cdt1 and Cdc6 in Li-Fraumeni cells. 
Panel below (e) and (f) presents p21 protein structure and domains. Location of 
mutations in the PIP motif of p21PCNA is also depicted. (g) Cdt1 and Cdc6 reduced 
turnover due to the cell cycle profile imposed by constitutive p21 expression. (h) 
Stabilization of Cdc6 by p21 over-expression. (i) Real-time RT-PCR assessment of 
Cdh1/Fzr1 in induced and non-induced Saos2 and Li-Fraumeni p21WAF1/Cip1 Tet-ON 
cells [*p = 0.02108 (Saos2), *p = 0.00479 (Li-Fraumeni), t-test, error bars indicate 
mean +/- SDs, n=3 experiments]. Actin and vinculin serve as loading controls, GAPDH 
serves as a normalizing housekeeping gene; h: hours; MG132: proteasome inhibitor; 
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CHX: cycloheximide. Uncropped images of in Supplementary Fig. S9. Source data 
are available in Supplementary Table 25. 
 
Figure 3. The status of p53 defines the ability of p21 to regulate the levels of Cdt1 
and Cdc6. Immunoblots (IBs) for Cdt1 and Cdc6 in (a) H1299 p21WAF1/Cip1–
Ponasterone-ON and (b) HT1080 p21WAF1/Cip1–IPTG-ON cells challenged with 
p21WAF1/Cip1. (c) IBs for Cdt1 and Cdc6 in Saos2 p53 Tet-ON cells upon p53 induction. 
Histogram illustrates apoptosis as assessed by flow cytometry analysis (FACS) after 
p53 induction (*p < 0.01, t-test, error bars indicate mean+/- SDs, n=5 experiments). (d) 
IBs for Cdt1 and Cdc6 in Saos2 cells treated with TGF-β (see also Supplementary Fig. 
S1eiii-iv). (e) FACS of HT1080 p21WAF1/Cip1–IPTG-ON cells showed that induction of 
apoptosis as well as Cdt1 and Cdc6 expression are p53-dependent upon p21 expression. 
Corresponding IBs for p53, Cdt1 and Cdc6 in the manipulated HT1080 p21WAF1/Cip1–
IPTG-ON cells. (f-h) FACS analysis of (f) Saos2- and (g) Li-Fraumeni-p21WAF1/Cip1 
Tet-ON cells showed an accumulation of cells with >4N DNA content (re-replication) 
after p21 induction that is Cdt1 and Cdc6 dependent (*p < 0.0001, ANOVA, error bars 
indicate mean +/- SDs, n=5 experiments). Similar analysis using (h) the p21PCNA mutant 
(see panel under Fig. 2e,f) abrogated re-replication (p = NS, t-test, error bars indicate 
mean +/- SDs, n=5 experiments). Actin serves as a loading control. Ctl: control short-
hairpin RNA; d: days; h: hours. Uncropped images of blots in Supplementary Fig. S9. 
Source data are available in Supplementary Table 25. 
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Figure 4. Sustained p21 expression triggers replication stress and DNA damage 
accumulation in a Cdt1/Cdc6-dependent manner in S-phase. (a) PFGE depicts 
DNA damage upon prolonged p21 expression. (b) Assessment of DNA breaks with 
comet assays in Saos2 p21WAF1/Cip1 Tet-ON induced for the indicated time points and 
after Cdc6, Cdt1 siRNA silencing or both. Red lines in inset magnifications depict 
comet (moment) tails. (c) p21 expression, in cells with non-functional p53, activated 
the DDR pathway in a Cdc6 and Cdt1-dependent manner (p < 0.0001, ANOVA, error 
bars; mean +/- SDs, n=3 experiments). (d-f) p21–dependent Cdc6 and Cdt1 
overexpression produces DNA damage and activation of the DDR pathway in a Cdc6 
and Cdt1-reliant manner in Li-Fraumeni p21WAF1/Cip1 Tet-ON cells as assessed by comet 
assay (d) and immunofluorescence analysis of DDR markers (e) (*p < 0.0001, ANOVA 
(d,e), p = NS, t-test (f), error bars; mean +/-SDs, n=3 experiments) (e). Comet assays 
using p21PCNA demonstrated absence of DNA damage (f). Red lines in inset 
magnifications label comet (moment) tails. (g) Reduced replication fork speed and 
replication fork asymmetry upon sustained p21 expression (*p < 0.001, p < 0.002, t-
test, ± indicate SDs, n=2 experiments). Saos2 p21WAF1/Cip1 Tet-ON non-induced vs 
induced cells (96h) after 20min consecutive labeling pulses of CIdU (red) and IdU 
(green) were subjected to DNA fiber analysis. (h-i) Protracted p21 expression inflicts 
DNA damage in S-phase in (h) Saos2 p21WAF1/Cip1 Tet-ON and (i) Li-Fraumeni 
p21WAF1/Cip1 Tet-ON cells. FACS of p21-induced cells for 96h and co-stained for 
γH2AX/Propidium Iodide (PI), with or without anti-Cdc6/Cdt1 siRNA targeting, and 
p21-induced cells for the indicated time points and co-stained for EdU/γH2AX. 
Histograms for γH2AX/PI depict counts in rectangular areas (both dashed and not) (* 
p < 0.0001, ANOVA and t-test respectively, error bars; mean +/- SDs, n=5 experiments). 
Actin, H2AX and vinculin serve as loading controls; Ctl: control siRNA; d: days; h: 
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hours; NS: non-significant. Uncropped images of blots in Supplementary Fig. S9. 
Scale bars 7.5 μm (c, e) or 50 μm (b, d, f). Source data are available in Supplementary 
Table 25. 
 
Figure 5. Extended p21 over-expression mediates accumulation of replication 
intermediate lesions that are processed by MUS81-EME1 and repaired by a 
Rad52-dependent mechanism. (a-c) Single-stranded DNA production in p21 over-
expressing cells (ON) compared to non-overexpressing cells (OFF). Scale bars: 25μm. 
(d) i) Electron micrograph of a representative reversed replication fork from p21-
induced Saos2 cells. Bars: (main images) 100 nm; (insets) 50 nm. Histogram depicts 
frequency of reversed replication forks. (brackets: total number of analyzed molecules, 
above each column: percentage of reversed forks). ii) Electron micrograph of a 
representative replication bubble with one side entirely single-stranded in p21-induced 
Saos2 cells. Bar, 100 nm. Histogram depicts frequency of replication bubbles. 
(brackets: total number of analyzed molecules; above each column: percentage of 
replication bubbles). iii) Electron micrograph of a representative replication fork in 
p21-induced Saos2 cells. Black arrow points to an ssDNA region. Bars: (main image) 
100 nm; (inset) 100 nm. Graphical distribution of ssDNA length at the junction (black 
arrow) in Saos2 p21WAF1/Cip1 Tet-ON and OFF cells. Only molecules with detectable 
ssDNA stretches are included in the analysis. The lines show the median lengths of the 
ssDNA regions at the fork in the specific set of analyzed molecules (* p ≤ 0.1; **, p ≤ 
0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001, Mann–Whitney-test) (brackets: total number of 
analyzed molecules) (P: parental duplex, D: daughter duplexes, R: regressed arm). (e-
g) p21 mediated DNA damage is processed by MUS81 resolvase (*p < 0.0001, 
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ANOVA). Red lines in inset magnifications label comet (moment) tails. Scale bars: 
50μm. FACS of Saos2 p21WAF1/Cip1 Tet-ON induced cells for 96h and co-stained for 
EdU/γH2AX, with or without anti-MUS81 silencing (f). (h) Silencing of Rad51 resulted 
in decreased γH2AX levels (*p < 0.01, t-test). (i-k) Suppression of Rad52 was followed 
by increased γH2AX expression and cell death (j) (*p < 0.0001, ANOVA), (l) Rad51 
promoter is occupied by E2F4 upon p21 induction as assessed by chromatin 
immunoprecipitation (ChIP) (*p < 0.000913, t-test). Actin and H2AX: loading controls; 
Ctl: control siRNA; h: hours. Uncropped images of blots in Supplementary Fig. S9. 
Error bars indicate mean +/- SD, n= 3 experiments in (e,g) comet assays, (h, i, k) blots, 
and (l) ChIP; n=5 experiments for (f, j) FACS analyses. Source data are available in 
Supplementary Table 25. 
 
Figure 6. Deregulated up-regulation of Cdc6 / Cdt1 links p53-independent 
activation of p21 with senescence. (a-c) Sustained p21 expression triggers senescence 
in (a) Saos2 p21WAF1/Cip1 Tet-ON (Scale bars: 20 μm) and (b) Li-Fraumeni p21WAF1/Cip1 
Tet-ON cells (Scale bars: 10 μm). (c) Induction of p21PCNA expression in Li-Fraumeni 
cells does not yield similar results. Cells grown on coverslips were stained to assess the 
senescent phenotype applying the Sudan Black-B protocol and SA-b-gal.66 (Scale bars: 
10 μm) (d-e) IBs depict p73 status upon siRNAs targeting Cdc6 and Cdt1, as well as 
the efficiency of anti-p73 treatment in (d) Saos2 p21WAF1/Cip1 Tet-ON and (e) Li-
Fraumeni p21WAF1/Cip1 Tet-ON cells. (f-g) Sustained p21 expression reduces p14ARF and 
p16INK4A protein levels in (f) Saos2 p21WAF1/Cip1 Tet-ON and (g) Li-Fraumeni 
p21WAF1/Cip1 Tet-ON cells. Actin serves as loading control; Ctl: control siRNA; h: hours. 
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Error bars; mean +/- SD, n=3 experiments. Uncropped images of blots are shown in 
Supplementary Fig. S9. Source data are available in Supplementary Table 25. 
 
Figure 7. Prolonged p21 expression, in cells with p53 loss of function, overrides 
the senescence barrier. (a-b) Morphological features observed by inverted-phase 
contrast microscope of escaped cells (20 days of p21 expression) in (a) Saos2 
p21WAF1/Cip1 Tet-ON and (b) Li-Fraumeni p21WAF1/Cip1 Tet-ON cells. Scale bars: 15μm 
(c-d) BrdU incorporation is restored to almost similar levels to non-induced cells after 
bypass of senescence in (c) Saos2 p21WAF1/Cip1 Tet-ON and (d) Li-Fraumeni 
p21WAF1/Cip1 Tet-ON cells (error bars indicate mean +/- SDs, n=3 experiments). Scale 
bars: 50μm. (e) EdU incorporation increases in p21WAF1/Cip1 expressing cells after 20 
days of continuous induction (error bars indicate mean +/- SDs, n=5 experiments). (f) 
Appearance of a significant sub-population of Cyclin A and p21 positive cells at 20 
days of induction. Double IF analysis of induced cells for Cyclin A and p21 at indicated 
time points (error bars indicate mean +/- SDs, n=3 experiments). Scale bars: 50μm. (g-
h) Restoration of Cdk2 activity and reduction of p73 levels [(g) Saos2 p21WAF1/Cip1 Tet-
ON and (h) Li-Fraumeni p21WAF1/Cip1 Tet-ON cells] in cells “escaping” senescence (see 
also Supplementary Fig. S2e). (i) Escaped cells depict larger nuclei than non-induced 
ones (staining with DAPI). Histogram depicts average values in the OFF versus ON 
groups, after 20 days (*p < 0.0001, t-test, error bars indicate mean +/- SDs, n=3 
experiments). Scale bars: 7.5μm. (j) Serial-section immunohistochemical (IHC) 
analysis showed co-expression of p21, Ki67 and Cdc6 in atypical cancer cells in clinical 
samples (see also Supplementary Fig. S2g). (Scale bars: 50μm). (k) DNA damage was 
significantly reduced in escaped cells. Comet assays showed DNA breaks in cells 
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induced for the indicated time points (error bars indicate mean +/- SDs, n=3 
experiments). Red lines in magnifications of insets label comet (moment) tails (TM) 
for length comparison. (Scale bars: 50μm). Actin serves as loading control; h: hours. 
Uncropped images of blots are shown in Supplementary Fig. S9. Source data are 
available in Supplementary Table 25. 
 
Figure 8. p21 expressing cells that have overridden (escaped) the senescence 
barrier demonstrate genomic instability and aggressive behaviour. (a) Increased 
frequency of micronuclei in “escaped” cells. Arrows depict micronuclei (*p = 0.0098, 
t-test, error bars indicate mean +/- SDs, n=3 experiments). (b-c) High resolution array-
Comparative Genomic Hybridization (aCGH) analysis between “escaped” p21 
expressing (b) Saos2- and (c) Li-Fraumeni-p21WAF1/Cip1 Tet-ON cells and non-induced 
ones at 30 days. Blue and red coloured regions along the chromosome ideograms depict 
genome gains and losses, respectively. Upper (b-c) insets depict narrow 
subchromosomal areas exhibiting alternating regions of gains or losses with retention 
regions in between (in blue and red shadowed rectangles, respectively), possibly 
indicating events of chromoanasynthesis and chromothripsis, respectively. (d-e) Circos 
diagrams depicting novel (d:175 and e:44) chromosomal rearrangements in “escaped” 
Saos2 (d) and Li-Fraumeni (e) p21WAF1/Cip1 Tet-ON expressing cells, respectively, 
revealed by whole-genome sequencing (human chromosomes are located at the 
perimeter). A representative breakpoint is also shown. (f-g) Representative results 
showing the high correlation between the aCGH, Next Generation Sequencing and 
cytogenetic analyses in “escaped” p21 cells. Dashed-white rectangles; gains or losses, 
yellow rectangles; translocations. (h,i,l) Escaped Saos2 p21WAF1/Cip1 Tet-ON cells (45 
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days of p21 expression) form more and larger colonies than cells with non-induced 
(OFF) p21 in soft agar assay (h). Escaped (i) Saos2- and (l) Li-Fraumeni- p21WAF1/Cip1 
Tet-ON cells also display invasion capability (p = 0.00373, p = 0.034, p = 0.000314 
(h,i); p = 0.0015 (l), t-test, error bars indicate mean+/- SDs, n=3 experiments). (j,m) 
Escaped (j) Saos2 p21WAF1/Cip1 Tet-ON and (m) Li-Fraumeni p21WAF1/Cip1 Tet-ON cells 
(at 20d) exhibit increased genotoxic drug tolerance. Histogram depicting increased IC50 
values by escaped cells upon treatment with Doxorubicin and Cis-platinum (p = 0.91, 
p < 0.0001, p = 0.013 (j); p = 0.38, p = 0.0005, p = 0.0001 (m); ANOVA, error bars 
indicate mean+/- SDs, n=3 experiments). (k) Escaped Saos2 p21WAF1/Cip1 Tet-ON cells 
(20d) demonstrate cancer stem cell-like traits as assessed by tumorsphere formation 
assay coupled to soft agar growth (p = 0.0045, p = 0.0151, t-test, error bars indicate 
mean +/- SDs, n=3 experiments). Source data are available in Supplementary Table 
25. 
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ONLINE MATERIALS and METHODS 
Tumour specimens 
Formalin-fixed, paraffin-embedded sections from 20 head-neck carcinomas, 30 
urothelial bladder carcinomas, 30 lung carcinomas and 5 dysplasia-associated lesions 
or masses (DALMs) from patients with ulcerative colitis, that exhibit early p53 
aberrations,17 were analyzed and have been previously described.14,67 Patients had not 
undergone any chemo-, immune- or radiotherapy. Protocols for clinical sample 
collection and their experimental use were approved by the Bio-Ethics Committee of 
Medical School of Athens, in accordance with the Declaration of Helsinki and local 
laws and regulations, following also written consent from the patients.  
 
Cell lines and culture treatments 
Cell lines were maintained in DMEM (Invitrogen) with 10% FCS (Invitrogen), 2mM l-
glutamine (Invitrogen), and 100μg/ml penicillin and streptomycin (Invitrogen) at 37°C 
and 5% CO2.  
p21WAF1 and p21PCNA were subcloned from pRc-CMV vectors into the pLVXTRE3G, 
correspondingly. Inducible Li-Fraumeni p21WAF1/Cip1 Tet-ON, Li-Fraumeni and Saos2 
p21PCNA Tet-ON cells were generated by introducing the p21WAF1- and the p21PCNA-
carrying pLVXTRE3G vectors in MDAH041 (Li-Fraumeni) fibroblasts and Saos2, 
respectively.18 Clones with clear p21WAF1 and p21PCNA expression were selected. 
Tet-ON inducible cell lines were treated with 1μg/ml Doxycycline (Applichem) and 
HT1080 p21WAF1-9 cells with 100μM IPTG (Ambion). Saos2 and MDA-MD-234 were 
treated with 5ng/ml TGF-β, while MCF cells with 2μM doxorubicin (Sigma). 
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Microphotographs were obtained with an inverted microscope (Axiovert S100; Carl 
Zeiss) equipped with CP-Achromat objectives and a charge-coupled device IRIS colour 
video camera (SSC-C370P; Sony), using Image Pro Plus v3.0 (Media Cybernetics) 
software. 
No cell lines used in this study were found in the database of commonly misidentified 
cell lines that is maintained by ICLAC and NCBI Biosample. All cell lines have been 
authenticated by STR profiling and are regularly tested to exclude mycoplasma 
contamination. 
 
siRNA transfections and retrovirus infections 
Cdc6, Cdt1, Rad52, Rad51, p21WAF1, CDH1/FZR-1 (Thermo Scientific) and Mus81, 
p73 (Santa Cruz) siRNA gene silencing was performed as described, following 
manufacturer’s instructions.46  
Saos2 cells were transiently infected with pMSCV, pMSCV-p21WAF1 or pMSCV-
p21PCNA (a mutant p21WAF1 harboring Q144, M147, F150 substitutions to A in its PIP 
degron motif) vectors using the Phoenix helper-free retrovirus producer cell line as 
previously described.49 
 
Immunohistochemistry (IHC) 
IHC was performed as previously published using the UltraVision LP Detection System 
(#TL-060-HD, Thermo Scientific) according to manufacturer’s instructions.67 Primary 
antibodies are described in Supplementary Table S23. Evaluation and controls for Ki-
67 and p21WAF1 have been previously described.67 
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Indirect Immunofluorescence (IF) 
Indirect IF analysis was performed as previously published.14 Primary antibodies are 
described in Supplementary Table S23. Secondary antibodies were Alexa Fluor® 488 
goat anti-rabbit (Invitrogen, #A11034, 1:500) and Alexa Fluor® 568 goat anti-mouse 
(Invitrogen, #A110-31, 1:500). Image acquisition of multiple random fields was 
automated on a ScanR screening station (Olympus, Germany) and analyzed with ScanR 
(Olympus, Germany) software, or a Zeiss Axiolab fluorescence microscope equipped 
with a Zeiss Axiocam MRm camera and Achroplan objectives, while image acquisition 
was performed with AxioVision software 4.7.1. 
 
Electron microscopy (EM) analysis of DNA RIs in human cells 
The procedure was performed as previously described.35 Images were obtained with a 
transmission electron microscope (Tecnai G2 Spirit; FEI; LaB6 filament; high tension 
≤120 kV) equipped with a side mount charge coupled device camera (2,600×4,000 
pixels; Orius 1000; Gatan, Inc), processed with DigitalMicrograph Version 1.83.842 
(Gatan, Inc.) and analyzed with Image J (National Institutes of Health). 
 
Protein extraction, cell fractionation and immunoblotting 
Protein extraction and cell fractionation (Supplementary Fig. S1di) was performed as 
described before.12,14 Primary antibodies are described in Supplementary Table S23. 
Thirty µg of protein from total extracts or 1μg of histones per sample, were adjusted 
with Laemmli Buffer (Sigma) and loaded on acrylamide/bis-acrylamide gels. Gel 
electrophoresis, transfer to PVDF membrane (Millipore) and signal development with 
nitro blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) solution 
(Molecular Probes) or chemiluminescence were performed as previously described.12 
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Alkaline phosphatase conjugated anti-mouse or anti-rabbit secondary antibody (1:5000 
dilution)(Promega) were used.  
 
In vivo ubiquitin assay 
Saos2 p21WAF1 cells were treated with MG-132 proteasome inhibitor (MERCK) for 3h 
at 30μM at the time points indicated (Fig. 2d). Cells were lysed in RIPA buffer [50mM 
Tris-HCL pH 8.0, 150mM NaCl, 0.1% SDS, 1% Sodium Deoxycholate, 1% Triton X-
100, protease inhibitor cocktail (Thermo Scientific), phosphatase inhibitor cocktail 
(Thermo Scientific), N-ethylameleimide deubiquitinase inhibitor (Applichem)]. 
Protein lysates were precleared with protein G agarose beads (Millipore) for 1hr and 
then incubated with G-protein beads bound to Cdt1 antibody (Supplementary Table 
S23) for 2 hours at 4oC. Beads were washed 3 times in RIPA buffer containing protease, 
phosphatase and deubiquitinase inhibitors, as above. Protein was eluted from beads 
with 2x SDS-β-mercaptoethanol sample buffer, boiled for 8 min and loaded on 
polyacrylamide gels for SDS-PAGE as described above. Blots were blocked for 1h in 
5% BSA in TBS-0.1% (v/v) Tween-20 solution at room temperature (RT). Membranes 
were incubated overnight with Cdt1 antibody (Supplementary Table S23) in 5% BSA 
in TBS supplemented with 0.1% (v/v) Tween-20, followed by a 1h incubation with 
HRP- conjugated anti-mouse secondary antibody (R&D Systems) at 1:1.000 dilution at 
RT. Signal development was performed with NBT/BCIP solution (Molecular Probes) 
according to manufacturer’s instructions. 
 
CDK2 kinase activity 
For each sample, 50mg of total-cell protein extract was precleared for 2h at 4°C with 
5mg of rabbit immunoglobulin G (anti-Cdk2) or 5mg of mouse immunoglobulin G 
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(anti-cyclin B1) prebound to protein A-Sepharose (Upstate-Millipore). Precleared 
lysates were collected and incubated with anti-Cdk2, or anti-cyclin B1with mixing for 
2h at 4°C. Protein A-Sepharose was added, and the samples were mixed for 2h at 4°C. 
The immunoprecipitates were washed twice with TBS and twice with kinase buffer 
(100mM Tris [pH 7.4], 20mM MgCl2, 2mM dithiothreitol) and incubated with 5mg of 
histone H1 (Boehringer Mannheim), 15nM ATP for 10min at 25°C. Samples were 
incubated with Malachite Green Reagent for 30min (Cdk2 and cyclin B1). Kinase assay 
mixtures were quantified at 620nm by subtracting negative control. 
 
Chromatin immunoprecipitation (ChIP) assay 
ChIP assay was performed as previously described.12 A 100bp fragment in the Rad51 
promoter and a 110bp amplicon, located approximately 1000bp from the transcription 
start site (Fig. 5l), were amplified. Primers and annealing temperatures are provided in 
Supplemental Table S24. PCR reactions containing 1% of the total chromatin extract 
used in the immunoprecipitation reactions were used as inputs. 
 
Comet Assay  
Was performed as previously described.12 Cells were observed under a Zeiss Axiolab 
fluorescence microscope equipped with a monochrome CCD camera. Analysis was 
conducted with Cometscore software (Tritek). All experiments were performed in 
triplicates. 
 
Pulsed-field gel electrophoresis (PFGE) 
Has been previously described.31  
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DNA fiber spreadings 
Was conducted as previously described with slight modifications.45 Briefly, Saos2 
p21WAF1/ cells were grown in the presence or absence of doxycyclin for 4 days and then 
pulsed-labeled with 25M CldU for 20min, and then labelled with 250M IdU for 
20min. Cells were then harvested and lysed on glass slides in spreading buffer. The 
DNA was denatured and stained with rat anti-BrdU/CldU (1:1000, OBT0030F, 
Immunologicals Direct) and mouse anti-IdU/BrdU (1:500, clone B44, Becton 
Dickinson) primary antibodies.  
 
Isolation of nucleic acids and bisulfate treatment 
DNA extraction was performed as previously described.14 RNA was extracted with the 
RNeasy Mini Kit (#74104, Qiagen). For assessing DNA methylation levels of p73 
promoter, 1 μg DNA was bisulphite-converted using the EZ-DNA Methylation Gold 
kit (ZymoResearch) as per supplier’s guidelines and eluted in 30 μl of elution buffer. 
 
cDNA preparation and real time (RT)-PCR 
cDNA generation and real-time reverse transcription PCR (RT-PCR) analysis was run 
as described before.67 DNA methylation levels for p73-promoter were assessed by high-
resolution-melting (HRM) analysis. The reaction was performed in a StepOne Real 
time machine (Life Technologies) using Universal Master Mix II w/o UNG containing 
SYBR (Life Technologies) and 200nM primers. A dissociation (melt) curve 
programme followed at the end of 40 cycles. Signal analysis was carried out using the 
StepOne v2.3 software. SssI methylated and unmethylated DNA was run in parallel as 
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positive and negative controls, respectively. Primer sequences and annealing 
temperatures are provided in Supplemental Table S24. Results are presented as n-fold 
changes for the various time points after p21WAF1 induction versus the values of the non-
induced sample. Mean value was calculated from three independent measurements. 
 
Flow cytometric analysis (FACS) 
Cell cycle analysis was assessed on a FACS Calibur (Becton-Dickinson) as described 
before.14 
For BrdU pulse-chase proliferation assays, cells were pulse-labeled with 10μM BrdU 
(Roche) for 1h, fixed in 70% ethanol, and incubated in 2M HCl for 30min. Cells were 
incubated with mouse antibody against BrdU (1:100) for 1h. For EdU analysis, cells 
were either pulsed for 10min or 24h with 10μM EdU. Cells were fixed in 70% ethanol 
and incubated with mouse anti–γ-H2AX or mouse anti-p21WAF1 for 30 min (see 
Supplementary Table 23), followed by further 15 min incubation with Alexa Fluor 
488 anti–mouse IgG (1:100, #A-11029, Invitrogen) or anti-mouse E-Phycoerythrin 
(1:100, Invitrogen). EdU was detected with a Click-iT EdU Cell Proliferation Assay kit 
(Invitrogen-C10420).  
For MCM2 staining, cells were washed once in wash buffer (1% (w/v) BSA in PBS), 
while unbound MCM2-7 was extracted in freshly prepared CSK buffer (10mM HEPES, 
100mM NaCl, 3mM MgCl2, 1mM EGTA, 300mM sucrose, 1% (w/v) BSA, 0.2% (w/v) 
Triton-X100, 1mM DTT, 1mM PMSF, 10ng/ml Pepstatin, 10ng/ml Leupeptin and 
10ng/ml Aprotinin) on ice for 10min. Extracted cells were then fixed in 2% (v/v) 
paraformaldehyde in PBS for 10min at 37°C, washed twice in wash buffer and stored 
in wash buffer at 4°C until staining. CSK extracted fixed cells were permeabilised in 
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ice cold 70% (v/v) ethanol for 10min at RT, washed in wash buffer and incubated for 
1h at RT with mouse monoclonal anti-human MCM2 (BM28 #610700, BD 
Biosciences) diluted 1:500 in wash buffer. Cells were then washed once in wash buffer 
and incubated for 30min at RT in the dark with Alexa Fluor 488 goat anti-mouse 
secondary antibody (#A-11029, Invitrogen) diluted 1:500 in wash buffer, before being 
washed twice in wash buffer and re-suspended in 50µg/ml 7-AAD (7-
aminoactinomycin D, Life Technologies) diluted in wash buffer. Samples were 
analysed using FACS Canto (Becton Dickinson) and the BD FACS DIVA software 
(BD Biosciences). Data analysis was performed using Flowjo (version 7.6.5, Tree Star 
Inc.). To quantify G1 MCM levels, the Flowjo software was used to gate on cells with 
a G1 DNA content and then the mean, median, 95th and 99th percentiles of the Alexa 
Fluor 488 levels in the G1 cells were calculated for each replicate; the data is presented 
with the background mean, median, 95th percentile or 99th percentile subtracted to 
correct for the increase in auto-fluorescence. 
 
Senescence staining 
Control (OFF) and induced (ON) Saos2 p21WAF1 Tet-ON or MDAH041 p21WAF1 Tet-
ON cells were fixed in 1% paraformaldehyde and then processed for Sa-β-gal or Sudan 
Black B staining and counterstained with nuclear fast red, as described elsewhere.66 
Only cytoplasmic staining was scored as positive signal. 
 
MTT Assay  
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Cytotoxicity was estimated by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay.12 Data from three independent measurements 
were averaged and corresponding s.d. is also reported. 
 
Soft agar and invasion assays 
Soft agar and invasion assays were performed as described elsewhere.12 Experiments 
were performed in three independent replicates. 
 
In vitro tumoursphere formation assays 
Saos2 Tet-On p21WAF1 (104) cells were suspended in sphere formation medium [serum-
free DMEM/F12 medium (Invitrogen) supplemented with 20ng/ml epidermal growth 
factor (EGF, Sigma), 20ng/ml basic fibroblast growth factor (bFGF, Sigma) and 1×B27 
supplement (Invitrogen)] in ultra-low attachment 6-well plates (Corning). Cells were 
cultured under 5% CO2 at 37°C for 15 days. Number of generated spheres were counted 
and sized under an inverted microscope (Axiovert S100; Carl Zeiss) equipped with CP-
Achromat objectives. Subsequently, medium with spheres were aspirated, treated with 
trypsin to dissociate cells from spheres and centrifuged (Fig. 8k). Cell pellets were 
resuspended in fresh medium, counted and plated on soft agar, as previously 
described.12 Data from three independent measurements from this combined procedure 
were averaged and corresponding s.d. is reported. 
 
Molecular Cytogenetics  
Molecular cytogenetics analyses were conducted as previously reported.12 Cytogenetic 
analyses were performed using a 63× magnification lens on a fluorescent Axio-Imager 
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Z1, Zeiss microscope, equipped with a MetaSystems charge-coupled device (CCD) 
camera and the MetaSystems Isis software. 
 
High-throughput analyses  
Proteomics  
Total protein was extracted from 2 biological replicates of non-induced and 12h, 48h 
and 96h induced Saos2-p21WAF1 Tet-ON cells (n=2 epxeriments), where protein 
Digestion and 8plex-iTRAQ Labeling was performed as previously described.16 The 
pooled whole sample was split in two equal parts lyophilized and stored at -20oC. To 
the first half of the aforementioned iTRAQ labeled sample High-pH Reverse Phase 
(RP) Peptide Fractionation was performed as previously described.16 The second half 
of the iTRAQ labeled peptides was fractionated with Hydrophilic Interaction 
Chromatography as previously described.68 
The individual high-pH RP and HILIC peptide fractions were analysed by LC-MS/MS 
followed by database searching as previously described.69 
 
High-throughput whole genome analyses 
aCGH analysis. Genomic DNA from 30 days induced and non-induced Saos2- and Li-
Fraumeni-p21WAF1 Tet-ON cells was extracted using the BioRobot® M48 System 
(Qiagen) and the MagAttract® DNA Blood Midi M48 Kit (Qiagen). Quality and 
quantity of the DNA samples was determined on a NanoDrop ND-1000 UV-VIS 
spectrophotometer.  
Agilent Human Genome CGH 4x180K [to analyze Saos2-p21WAF1 escaped and non-
induced, each comprising 2 biological replicates] and 1x1MK [to analyze i. Saos2-
p21WAF1 escaped and non-induced, each comprising 2 biological replicates, and ii. Li-
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Fraumeni-p21WAF1 escaped and non-induced, each comprising 3 biological replicates, 
(n=3)] microarrays were used. Labelling and hybridization was carried out according 
to manufacturer’s guidelines. Data were processed using Feature Extraction 10.7.3.1 
and analysed using Cytogenomics 2.7.22.0 software (Agilent) with the following 
settings: Algorithm: ADM-1, Threshold: 6.7, with a minimum of 4 probes for a region 
to be included. Centralization and fuzzy zero corrections were applied to remove 
putative variant intervals with small average log2 ratios as compared to the noise-level 
which was determined by the system.  
Whole genome sequencing (WGS). Genomic DNA from two biological replicates 
obtained at 30 days induction and non-induction of Saos2- and Li-Fraumeni-p21WAF1 
Tet-ON cells, respectively, was used for WGS. The library preparation and the WGS 
were carried out in the Greek Genome Center (GGC) of Biomedical Research 
Foundation of Academy of Athens (BRFAA) and in EMBL Genecore facility. 
WGS was performed achieving 20-30x coverage of the human genome with paired-end 
sequencing (2x150 and 2x100 bp). Quality control was performed with fastqc 
software70 and alignment to the human genome (GRCh37/hg19 version) was performed 
with bowtie2 algorithm.71 Samtools72 was used to convert sam files to bam and for 
sorting bam files. Breakdancer software73 (breakdancer-1.1-2011_02_21 version) was 
utilized in order to identify SV (intra- and inter-chromosomal translocations, deletions, 
insertions and inversions).  
Use of breakdancer with default parameters led to identification of new inter-
chromosomal translocations in “ON” versus “OFF” cells in both cell types 
(Supplementary Fig. S7). In order to identify microhomology regions in the inter-
chromosomal translocations observed in both systems we used the coordinates from the 
breakdancer output and extended 30bp on both sides of the breakpoint-junction. Clustal 
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W was used for aligning the regions around the breakpoint junctions. Microhomology 
regions identified on the breakpoint spanned from 2-38bp. 
RNA-seq analysis. RNA was collected from non-induced, 10 days (10d) and “escaped” 
Li-Fraumeni p21WAF1/Cip1 Tet-ON cells [six biological replicates for escaped (n=6) and 
four biological replicates for non-induced (n=4)]. RNA-seq library preparation and 
analysis procedure was performed as described before.8 
Expression microarray analysis. Total RNA was isolated from three biological 
replicates of non-induced and 12h, 48h and 96h induced Saos2-p21WAF1 Tet-ON cells 
(n=3), using RNeasy Total RNA kit (Qiagen) following the manufactures instructions. 
Microarray analysis was performed by the microarray unit of CBM Core Facility Italy 
(http://www.cbm.fvg.it) using Illumina’s Whole-Genome Expression Beadchip. 
Integrity of total RNA was evaluated using capillary electrophoresis (Bioanalyzer 2100, 
Agilent) and quantified using a Nanodrop 1000. Aliquots of RNA (250 ng) samples 
were amplified according to specifications of the Illumina® TotalPrep™ RNA 
Amplification Kit (Ambion) to produce a pool of biotin-labeled RNA corresponding to 
the polyadenylated (mRNA) fraction. The cRNA samples were applied to whole-
genome HumanHT-12 v4.0 arrays (Illumina) and hybridized according to 
manufacturer’s specification. The hybridization images signal intensities were 
extracted and background subtracted using Illumina Inc. BeadStudio (v3.3.7). Data 
were checked for the Illumina internal quality control. 
Total RNA was extracted from the non-induced and “escaped” Saos2-p21WAF1 Tet-ON 
cells using Trizol (Life Technologies) and choloroform/isoamyl alcohol (49:1) [four 
biological replicates for escaped (n=4) and three biological replicates for non-induced 
(n=3)]. Targets were prepared using the GeneChip Whole Transcriptome (WT) Plus 
reagent kit and hybridized to Affymetrix GeneChip Human Transcriptome array 2.0 
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(HTA 2.0). The obtained Saos2-p21WAF1 transcriptome profile was compared with the 
Li-Fraumeni p21WAF1 transcriptome profile obtained by RNA-seq. 
 
Bioinformatic analysis 
Transcriptome and Proteome analyses from non-induced, 12h, 48h and 96h induced 
Saos2-p21WAF1 Tet-ON cells. Protein and gene ratios (time-point/time-0) were log(2) 
transformed and centered. Statistically significant differentially expressed genes and 
proteins (p<0.05) where determined by the log-2 ratios normal distributions and 
ANOVA plus Kruskal-Wallis (Kruskal Wallis only for the transcriptome data-set where 
n=3) since there were more than one time-points. For the proteomic dataset that 
consisted of two biological replicates, ANOVA was utilized based on the conclusion of 
previous reports74 that there are no principal objections to using t-test and ANOVA with 
sample replicates as small as 2. All calculations were performed with R. The “Gene-
Set Enrichment Analysis” on the Gene-Ontology Biological-Process set was performed 
as previously described.16 Pathway visualization for all data-sets was performed with 
Ariadne Genomics Pathway Studio v9.0.  
Transcriptome analysis from non-induced and “escaped” Saos2-p21WAF1 Tet-ON cells. 
Affymetrix .CEL files were normalized with the Robust Multi-array Average (RMA) 
algorithm. Data were further analyzed by Principal Component Analysis and one-way 
ANOVA (p<0.05). Differentially expressed transcripts were analyzed using the 
Ingenuity Pathway Analysis software considering all direct and indirect relationships 
obtained only from experimentally verified information.  
WGS and aCGH data comparison. To compare the WGS data with the aCGH one 
regarding DNA copy number aberrations in “escaped” (ON) cells versus control (OFF) 
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cells (both in Saos2 and Li-Fraumeni systems), the WGS data were processed as 
follows: a) Genomic regions presenting less than 10-times coverage were filtered out 
to ensure data high-quality, b) The log2 of the ratio of the normalized reads in the 
“escaped” cells  over the normalized number of reads in the control-cells was 
calculated, c) For each chromosome the aforementioned log2-ratios underwent DNA 
copy-number segmentation analysis utilizing the circular binary segmentation 
algorithm through the Bioconductor package “DNAcopy”.75 
Assessment of randomness in the overlap between the transcriptomics and aCGH data 
through Monte-Carlo simulation. To access the probability of the observed overlap 
between the transcriptionally affected genes (DNA-microarray for Saos2 and RNA-Seq 
for Li-Fraumeni p21 Tet-ON systems) and the genes present in the significantly 
affected genomic regions (aCGH data) being due to chance, a Monte-Carlo simulation 
approach was utilized. Specifically, the genes present on the corresponding 
transcriptomics analysis platform (DNA-microarray for Saos2 and RNA-Seq for Li-
Fraumeni) were randomly sampled 104 times with a sample size equal to the number of 
significantly regulated genes. For each random sampling the overlap with the genes 
present in regions exhibiting genomic aberrations according to aCGH was calculated. 
The distribution of the number of overlaps was found to be normal according to the 
Kolmogorov-Smirnov test for normality; hence the p-value of the observed overlap in 
our data was calculated. That p-value represents the probability of the observed overlap 
to belong to the distribution of the randomly generated overlaps, therefore being due to 
chance alone. All statistical analysis was carried out with R. Pathway Analysis. 
Proteomics and transcriptomics data were analyzed with Ariadne Pathway Studio v9.0 
as previously described.16 
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Statistics and Reproducibility 
Parametric (two-sided t-test and one-way ANOVA) and non-parametric tests (Mann–
Whitney and Kolmogorov-Smirnov test for normality), were used for hypothesis testing 
with p-values <0.05 considered as significant. 
Immunoblots presented in Figures 1e; 3a,b,d,e; 4a,c; 6d-g are representative over 3 
different experiments. Photos of Figures 1d, 5a-d, 7a-b are representative over at least 
two independent experiments. 
 
Data availability 
Microarray, aCGH and RNAseq data that support the findings of this study have been 
deposited in the Gene Expression Omnibus (GEO) under accession codes GSE62166 
(microarray), ... (aCGH), SRP045212 and  SRP074843 (WGS), and SRP074688 
(RNAseq), respectively. 
The proteomics dataset were deposited at ProteomeXchange Consortium via the PRIDE 
partner repository with the dataset identifier PXD004140. 
Source data for Fig. 2-8 and Supplementary Fig. 1-3 have been provided as 
Supplementary Table 25. All other data supporting the findings of this study are 
available from the corresponding author on reasonable request. 
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Supplementary materials legends 
 
Supplemental Figure legends 
 
Supplementary Figure 1. (a) Representative factors affected by p21WAF1/Cip1 induction 
at transcriptional and translational level. Representative real-time RT-PCR analyses to 
validate the high-throughput expression results (see also Fig. 2) (p < 0.01, t-test, error bars 
indicate mean +/- SDs, n=3 experiments). i. Mitotic factors: PLK1, AURKB, BUB1, 
BUB1B, KIF23 and the pro-apoptotic factor GLIPR1 along with the suppressor of the 
p21WAF1/Cip1 mediated effects ID1 are transcriptionally downregulated at the indicated time 
points in Saos2 p21WAF1/Cip1 Tet-ON induced cells. Growth factor IGFBP5, the ion channel 
encoding gene TRPM8 and the poly-A binding protein PABPC1L are upregulated. PBGD: 
Porphobilinogen deaminase (house-keeping gene) ii. Representative immunoblots that 
validate the proteome. Actin serves as a loading control. (PLK1: Polo-like kinase-1; 
AURKB:  Aurora kinase B; BUB1: budding uninhibited by benzimidazoles 1 homolog; 
KIF23:  kinesin family member 23; GLIPR1: Glioma pathogenesis related 1; ID1: inhibitor 
of DNA binding 1; IGFBP5: insulin-like growth factor binding protein 5; TRPM8: 
transient receptor potential cation channel subfamily M member 8; PABPC1L: poly(A) 
binding protein, cytoplasmic 1-like; TOP2A: topoisomerase 2A)  
(b) Timeline of senescence appearance in Saos2 p21WAF1/Cip1 Tet-ON and Li-Fraumeni 
p21WAF1/Cip1 Tet-ON induced cells. Activation of the senescence barrier occurs at 
approximately day 3 of induction in both cellular systems and increases gradually, reaching 
its highest value at around day 10, while no signs of senescence are evident in untreated 
cells grown for the same time period (as corresponding graphs depict). p21WAF1/Cip1 was 
confirmed by western blot (upper right panel).  
(c) i. E2F1 is upregulated while Chk1 is activated upon prolonged p21WAF1/Cip1 induction. 
Lysates from Saos2 p21WAF1/Cip1 Tet-ON cells, after treatment with 1µg /ml Doxycycline 
for the depicted time points, were separated by SDS-PAGE and immunoblotted to detect 
the indicated proteins. ii. Silencing of Cdh-1/FZR-1 leads to increase in E2F1 expression 
in the p53 null H1299 cells. iii. A decline of Cdk2 activity is observed following 
p21WAF1/Cip1 induction. Histogram depicting decreased Cdk2 activity at days 4 after 
p21WAF1/Cip1 induction.  
(d) MCM2-7 chromatin loading is increased following p21WAF1/Cip1 induction in Saos2 
and Li-Fraumeni cells. i. Diagram describing cell fractionation experimental algorithm. 
ii-iii. All fractions were separated by SDS-PAGE and were analyzed by IB in Saos2 cells 
(ii) and Li-Fraumeni cells (iii). Lamin-B serves as fractionation control, while β-tubulin as 
loading control (n=3 experiments). iv. FACS analysis of MCM2 chromatin loading in 
induced Saos2 p21WAF1/Cip1 Tet-ON cells versus non-induced (red dots, -ve: control 
experiment with no MCM2 antibody; blue dots, +ve: experiment with MCM2 antibody) (* 
p < 0.05, ** p < 0.01, *** p < 0.005, t-test, error bars indicate mean +/- SDs, n=3 
experiments).  
(e) Re-replication and DNA damage was significantly lesser in Saos2 cells infected 
with p21PCNA mutant. i. Comet assays showed DNA breaks in cells infected with the 
indicated constructs (see also Fig. 4b,d,f) (p < 0.0001, ANOVA, error bars indicate mean 
+/-SDs, n=3 experiments). Red lines in magnifications of insets label comet (moment) tails 
for length comparison. ii. FACS analysis of the corresponding treatments. iii. DNA damage 
is p21WAF1/Cip1 dependent in Saos2 cells treated with TGF-β (n=3 experiments). iv. 
p21WAF1/Cip1 dependent DNA damage, in Saos2 cells treated with TGF-β, is exerted via 
Cdc6/Cdt1 mediated replication stress. (Empty vector: pMSCV, p21PCNA: mutant 
p21WAF1/Cip1 harboring Q144, M147, F150 substitutions to A in its PIP degron motif)  
Source data can be found in Supplementary Table 25. 
 
Supplementary Figure 2. (a) Silencing of p21WAF1/Cip1 in induced (ii.) Saos2- and (iii.) Li 
Fraumeni- p21WAF1/Cip1 Tet-ON cells alleviates replication stress, DNA damage, 
senescence induction and enhanced resistance to chemotherapeutic drugs. Timeline of the 
experimental procedure is also depicted (i.). cells (p = NS, t-test or ANOVA, error bars 
indicate mean +/- SDs, n=3 experiments) Bars: 20μm (IF), 30μm (comet) 
(b) PCNA staining patterns reveal that sustained p21WAF1/Cip1 expression, in cells with 
non-functional p53, “traps” cells mainly in early S-phase. IF analysis for assessing 
PCNA staining patterns in non-induced and 96h induced cells. Histograms depict average 
of observed patterns in the induction conditions employed (mean +/- SDs, n=3 
experiments). Scale bars: 10 µm.   
(c) Absence of nascent ssDNA in Saos2 p21WAF1/Cip1 Tet-ON expressing cells. 
p21WAF1/Cip1 expression was induced for 96h with 1µg/ml doxycycline. The newly 
synthesized DNA was labeled for 20 min with 10 µM BrdU. 2 mM HU and 5 µM ATRi 
were added after the BrdU pulse as indicated for 2 h. After the indicated treatments, cells 
were fixed and stained with antibodies against BrdU without DNA denaturation to 
selectively detect nascent-strand ssDNA. Bars: 40μm. 
(d) P21WAF1/Cip1 mediated DNA damage is processed by MUS81 resolvase. i. IF staining 
of DDR markers (53BP1 and γH2AX) in Saos2 p21WAF1 Tet-ON induced cells for 96h, 
with or without anti-MUS81 siRNA targeting. Histogram depicts quantification of 53BP1 
and γH2AX foci/cell (p < 0.01, t-test, error bars indicate mean +/- SDs, n=3 experiments). 
Bars: 20μm. ii. DNA damage assessed by comet assay after prolonged expression in Li-
Fraumeni p21WAF1 Tet-ON cells (p < 0.01, t-test, error bars indicate mean +/- SDs, n=3 
experiments). Bars: 50μm. iii. Silencing of the homologous repair recombinase Rad51 
resulted in decreased γH2AX levels in Li-Fraumeni p21WAF1 Tet-ON cells (p < 0.0001, 
ANOVA, error bars indicate mean +/- SDs, n=3 experiments).  
(e) Sustained expression of p21WAF1/Cip1 in cells with non-functional p53 leads to 
restoration of Cdk2 activity in “escaped” cells. i. Following an initial decline (days 2-
12) Cdk2 activity is increased in “escaped” cells (after day 20) (p < 0.01, t-test, error bars 
indicate mean +/-SDs, n=3 experiments). ii. Expression levels of p21WAF1/Cip1 in the 
“escaped” (i) Saos2 and (ii) Li-Fraumeni p21WAF1 Tet-ON cells were similar or even higher 
sometimes (see Fig. 7g) to those observed in the initial phase of p21WAF1/Cip1 induction.  
(f) Potential mechanisms involved in p73 down regulation in the “escaped” Saos2- 
and Li-Fraumeni-p21 cells. (see Fig 7g) i. Absence of p73 promoter methylation and 
genetic loss at TP73 locus (1p36.33) (see Supplementary Fig. S5, S6; Supplementary 
Table 4). Representative result from real-time PCR followed by high resolution melting 
(HRM) analysis is depicted (n=3 experiments). Ctl DNA: SssI methylated and 
unmethylated control DNA. ii. Bioinformatic analysis employing Ingenuity software 
revealed potential factors that regulate p73 expression and activity. EGR-1 (Early Growth 
Response-1) is a potent transcriptional up-regulator of p73.51 In turn, p73 can also 
transcriptionally induce EGR-1exprresion, forming a positive feed-back loop. HECW2 
(ΗECT, C2 αnd WW Domain Containing E3 Ubiquitin Protein Ligase 2) expression 
stabilizes p73 protein levels via mono-ubiquitination,75 while PRKACB (Protein Kinase A 
Catalytic Subunit β) decreases p73 transactivation and intramolecular interaction 
capacity.76 iii. TP73 gene locus organization and structure of p73 protein with HECW2 and 
PRKACB interacting domains. Yellow rectangles: transcribed non translated TP73 exons; 
Blue rectangles: transcribed TP73 exons; Green rectangle: P1 promoter of TP73 gene; Blue 
ovals: EGR-1 biding sites. TDA: transactivation domain; DBD: DNA binding domain; OD: 
oligomerization domain; SAM: sterile alpha-motif domain. iv-v. Analysis of EGR-1, 
HECW2 and PRKACB expression status in “escaped” Saos2 p21WAF1/Cip1 cells at mRNA 
(iv.) and protein (v.) level validated results obtained from high-throughput transcriptome 
analysis (Supplementary Fig. S3). CREB phosphorylation was examined as a proof-of-
concept for PRKACB activity. vi. Analysis of EGR-1 at mRNA and protein level in 
“escaped” Li-Fraumeni p21WAF1/Cip1 cells (fold difference mean +/- SDs, n=3 experiments). 
vii. Potential mechanism for p73 downregulation in “escaped” cells. Decreased levels of 
EGR-1 possibly represent the main reason for low p73 expression.49 Additionally, high 
levels of PRKACB decreases p73 transactivation and intramolecular interaction abilities,76 
counteracting the ability of high HECW2 expression to stabilize p73 via mono-
ubiquitination.75 High PRKACB levels may contribute further to p73 down-regulation by 
interfering with the positive feed-back loop between ERG-1 and p73.76 (g) Serial-section 
immunohistochemical (IHC) analysis showed co-expression of p21WAF1/Cip1, Ki67 and 
Cdc6/Cdt1 in atypical cancer cells in head and neck carcinomas, urothelial carcinomas and 
precancerous lesions. Actin serves as a loading control. Source data can be found in 
Supplementary Table 25. 
 
Supplementary Figure 3. Differentially expressed genes whose expression status 
affects cancer according to literature in Saos2- and Li-Fraumeni-p21 cells. Expression 
status of genes associated with cancer progression (see also Supplemental Table 8). (a) 
Timeline of experimental planning of transcriptome analyses. (b) Principal Component 
Analysis (PCA) of the differentially expressed genes depicting the majorly different gene 
expression signatures over the (19540 in Saos2- and 25376 in Li-Fraumeni cells) 
transcripts analysed. (c) Validation of representative factors in “escaped” (ON) cells versus 
non-induced (OFF) Saos2 and Li-Fraumeni cells. Representative real-time RT-PCR 
analyses, validating the high-throughput expression analysis (p < 0.01, t-test, error bars 
indicate mean +/- SDs, n=3 experiments). (d) Relative expression levels given as log-2-
ratios of differentially expressed genes (p < 0.05) of the “escaped” vs OFF-cells, whose 
expression status (up or down-regulated) is reported to promote carcinogenesis. Arrow (←) 
denotes genes conferring cancer stemness (see also Supplemental Tables 8Aa, 8Ba). 
Lysates from non-induced and escaped Saos2 p21WAF1/Cip1 Tet-ON cells were 
immunoblotted to verify representatively the expression of the LGR5 cancer related 
stemness gene. (e) Differentially expressed genes whose expression status either promotes 
or suppresses cancer according to literature. Relative expression levels given as log-2-
ratios of differentially expressed genes (p < 0.05) of the “escaped” vs OFF-cells. The 
lengths of the “encircled” lines depict the intensity of expression. Uncropped images of 
blots are shown in Supplementary Fig. S9. Source data can be found in Supplementary 
Table 25. 
 
Supplementary Figure 4. “Escaped” Saos2 p21WAF1/Cip1 cells exhibit increased 
genomic instability relative to non-induced cells. (a) Timeline of experimental planning 
of genomic analyses. (b) Overview of all array-CGH (aCGH) analyses results. In total 41 
aberrations were found involving all chromosomes (except 9, 12, 14 and 15). The 
aberrations included 19 gains and 22 losses (Supplemental Table 5). The majority of 
aberrations were concentrated in chromosomes 3, 10 and X (Supplemental Table 5). 
[reference (Ref) genome is from un-induced (0 d) Saos2 p21WAF1/Cip1 cells] (c) Novel clonal 
rearrangements distinguish the “escaped” Saos2 p21WAF1/Cip1 (ON) from OFF cells [arrows 
indicate lost (in OFF cells) or rearranged (in “escaped”-ON cells) chromosomes]. The 
p21WAF1/Cip1-OFF cells (control), were mainly hypotriploid (51-56 chromosomes) and 
shared most of the characteristic structural chromosome aberrations of the parental Saos2 
cell line.77 Compared to these cells, the “escaped” ones remained hypo-triploid but 
displayed at least 10 novel clonal structural or numerical aberrations affecting 
chromosomes 2, 3, 5, 8, 11, 13, 14, 20, 21 and X. Large portions of chromosomes X and 
13 were lost in 90% of the “escaped” cells, confirming the aCGH findings. Furthermore, 
differential imbalances of chromosomes 5 and X between Saos2 p21WAF1/Cip1 ON cells and 
the controls were observed. In “escaped” (ON) cells, an additional inverted duplication of 
5p was also present in 90% of the examined nuclei. (d) The Saos2 p21WAF1/Cip1 ON cells 
exert significantly higher rates (two fold) of random structural CIN/chromosome as 
compared to controls. (CIN:chromosomal instability) (e) Genomic distribution of 
breakpoints of random structural chromosome anomalies. Telomeric regions were found 
to be most frequently affected by fusions, translocations and tandem duplications of large 
chromosome segments. As unidentified ones were categorized the non-telomeric, non 
centromeric genomic rearrangements in which the cytogenetic bands of their breakpoints 
remained obscure. (f) “Escaped” Saos2 p21WAF1/Cip1 cells exhibit increased karyotypic 
aberrations relative to non-induced cells. Comparative pseudo-colored M-FISH/SKY 
karyograms of 10 non-induced (OFF) Saos2 p21WAF1/Cip1 cells (588 chromosomes) and 10 
“escaped” (ON) ones (639 chromosomes), for the evaluation of whole genome structural 
CIN at the 350 chromosome band level. Arrows (and dashed rectangles) indicate 
representative non-clonal random structural rearrangements (unique anomalies 
encountered in a single cell). The “escaped” p21WAF1/Cip1 expressing cells (ON) displayed 
significantly higher rates of genome wide, random structural chromosomal 
rearrangements. ON cells (upper panel): Cells #1 and #7, from the Saos2 p21WAF1/Cip1 OFF 
panel, represent a minor subclone (20%) of this population because they share a distinctive 
clonal rearrangement affecting a derivative chromosome X and a deletion of 12p. Cells #3 
and #5, belong to a second subclone of the control cells that is characterized by a deletion 
of a rearranged chromosome 19. The remaining non-induced (OFF) p21WAF1/Cip1 cells #2, 
#4, #6, #8 and #10, display a homogeneous karyotypic constitution and represent the major 
clone. Cell #9 is a polyploid product of whole genome endoreduplication of the major clone 
of Saos2 p21WAF1/Cip1 OFF cells. “Escaped”-OFF cells (lower panel): Cells #1 and #6 
differ from the majority of the “escaped” (ON) population as they share a clonal inverted 
duplication of the long arm of chromosome 21. In addition, cells #2, #4 and #9, have lost 
a marker translocation der(9)t(5;9) that was replaced by a deletion 9p and acquired clonally 
an extra translocated der(22)t(20;22). A unique subclonal finding in Cells #3 and #10, of 
the “escaped” (ON) cells is the persistence of der(9)t(5;9). Cells #5 and #7 represent two 
different endoreduplicated ON subclones, characterized by unique structural abnormalities 
of chromosomes 7, 15 and 6 respectively. The karyotypic constitution of cell #8, resembles 
that of the control population and justifies the presence of an additional subclone that does 
not exceed the 10% of the “escaped” (ON) cells. (CIN:chromosomal instability)  
 
Supplementary Figure 5. Correlation between aCGH replicates and corroboration 
with the cytogenetically detectable novel clonal alterations in Saos2 p21 cells (* see 
also Fig. 8f). [reference (Ref) genome is from un-induced (0 d) Saos2 p21WAF1/Cip1 cells] 
 
Supplementary Figure 6. Correlation between aCGH and deep sequencing in Saos2 
(a) and Li-Fraumeni (b) cells (Next Generation Sequencing: NGS) analyses. Data from 
all replicates for each application were averaged before comparison. 
 
Supplementary Figure 7. Novel chromosomal rearrangements and microhomology 
regions related to breakpoints in (a) Saos2 and (b) Li-Fraumeni cells. Circos diagrams 
depicting novel chromosomal rearrangements in “escaped” Saos2 (a) and Li-Fraumeni (b) 
p21WAF1/Cip1 Tet-ON expressing cells, respectively, revealed by deep sequencing (human 
chromosomes are located at the perimeter). Data from two biological replicates are 
depicted. Circos in the middle show shared chromosomal rearrangements by the two Saos2 
(a) and Li-Fraumeni (b) p21WAF1/Cip1 Tet-ON biological replicates. Breakpoints employing 
micro-homologies ≥ 4bp in Saos2 (a) and ≥ 3bp in Li-Fraumeni (b) p21WAF1/Cip1 Tet-ON 
cells, respectively, are also presented below each circus diagram. Cytogenetic analyses (see 
also Supplementary Fig S4) confirming NGS data on breakpoints in the “escaped” Saos2 
p21WAF1/Cip1 Tet-ON expressing cells are also shown. Asterisk (a) denotes breakpoint that 
does not encompass a micro-homology. Continuous red line denotes position of 
breakpoints. 
 
Supplementary Figure 8. Relative gene expression levels (log-2 ratios) at 12, 48, 96-hs 
after p21WAF1/Cip1 -induction as well as “escaped” versus OFF cells in (a) Saos2 and 
relative gene expression levels (log-2 ratios) at 10 days after p21WAF1/Cip1 -induction as 
well as “escaped” versus OFF in (b) Li-Fraumeni cells. (c) Proposed model. (a) A: 
Relative expression of all measured genes (19540) at each depicted time-point as compared 
to non-induced cells (OFF). The correlogram at the bottom which presents the Pearson 
correlation coefficient among the 4 datasets illustrates that the overall gene-expression of 
the “escaped” population is non-correlated (~0 correlation coefficient) to the three prior 
time points, which amongst them present a high degree of correlation. B: Relative 
expression of genes presenting differential expression (p < 0.05) in the “escaped” cells in 
relation to OFF (553 genes). The correlogram at the bottom illustrates the absence of 
correlation between the “escaped” population with the three early time points (12, 48, 
96hs). C: Relative expression of commonly differentially expressed genes (42) (p < 0.05) 
at each time-point versus OFF. Special interest present the 16 out of 42 marked genes 
whose expression levels are reversed at the “escaped” population in comparison to the 
previous time-points. 
(b) The same heatmaps are presented for Li-Fraumeni cells. A:  Relative expression of all 
measured genes (25367) at each depicted time-point as compared to non-induced cells 
(OFF). B: Relative expression of genes presenting differential expression (p < 0.05) in the 
“escaped” cells in relation to OFF (3507 genes). C: Relative expression of commonly 
differentially expressed genes (538) (p < 0.05) at each time-point versus OFF. Special 
interest present the 154 out of 538 marked genes whose expression levels are reversed at 
the “escaped” population in comparison to 10-days. 
(c) Proposed model depicting prolonged p53-independent p21 oncogenic action (for 
additional mechanistic explanations see discussion). Under “physiological” conditions, 
MDM2 degrades p53.4,10 Dashed lines depict ineffective pathway. 
 
Supplementary Figure 9. Unprocessed blots/gels employed in the current manuscript. 
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Supplementary Table legends 
 
 
Supplementary Table 1. Molecules involved in key cellular processes displaing 
bimodality in cancer. 
 
Supplementary Table 2. Results from mRNA expression analysis on the Illumina whole-
genome HumanHT-12 v4.0 arrays, showing gene transcripts affected at 12h, 48h and 96h 
upon sustained p21WAF1/Cip1 induction in Tet-ON, Saos2-p21WAF1/Cip1. Three biological 
replicates (n=3) were used for the analysis of each time point (0,12,48,96). 
 
Supplementary Table 3. Results from mRNA expression analysis on the Illumina whole-
genome HumanHT-12 v4.0 arrays, showing gene transcripts (from Table 2) responding 
early upon sustained p21WAF1/Cip1 induction in Tet-ON, Saos2-p21WAF1/Cip1. Three 
biological replicates (n=3) were used for the analysis of each time point (0,12,48,96). 
 
Supplementary Table 4. Results from mRNA expression analysis on the Illumina whole-
genome HumanHT-12 v4.0 arrays, showing gene transcripts (from Table 2) responding at 
intermediate time upon sustained p21WAF1/Cip1 induction in Tet-ON, Saos2-p21WAF1/Cip1. 
Three biological replicates (n=3) were used for the analysis of each time point (0,12,48,96). 
 
Supplementary Table 5. Results from mRNA expression analysis on the Illumina whole-
genome HumanHT-12 v4.0 arrays, showing gene transcripts (from Table 2) responding 
late upon sustained p21WAF1/Cip1 induction in Tet-ON, Saos2-p21WAF1/Cip1. Three biological 
replicates (n=3) were used for the analysis of each time point (0,12,48,96). 
 
Supplementary Table 6. Results from proteomic analysis showing proteins affected at 
12h, 48h and 96h upon sustained p21WAF1/Cip1 expression in Tet-ON, Saos2 
p21WAF1/Cip1. Data show the mean of two biological replicates for each time point 
(0,12,48,96).  
 
Supplementary Table 7. Results from proteomic analysis showing proteins (from 
Supplementary Table 6) responding early upon sustained p21WAF1/Cip1 expression in 
Tet-ON, Saos2 p21WAF1/Cip1. Data show the mean of two biological replicates for each time 
point (0,12,48,96). 
 
Supplementary Table 8. Results from proteomic analysis showing proteins (from 
Supplementary Table 6) responding at intermediate time point upon sustained p21WAF1/Cip1 
expression in Tet-ON, Saos2 p21WAF1/Cip1. Data show the mean of two biological replicates 
for each time point (0,12,48,96). 
 
Supplementary Table 9. Results from proteomic analysis showing proteins (from 
Supplementary Table 6) responding late upon sustained p21WAF1/Cip1 expression in Tet-ON, 
Saos2 p21WAF1/Cip1. Data show the mean of two biological replicates for each time point 
(0,12,48,96). 
 
Supplementary Table 10. Results from aCGH analysis in Li-Fraumeni p21WAF1/Cip1 Tet-
ON “escape” vs non-induced (OFF) cells (Agilent G3 CGH 1M arrays). “Escaped” cells 
acquired chromosomal aberrations, in the form of gains and losses that ranged in size from 
approximately 1.75Kb to 92Mb. 
 
Supplementary Table 11. Results from aCGH analysis in Li-Fraumeni p21WAF1/Cip1 Tet-
ON “escape” vs non-induced (OFF) cells (Agilent G3 CGH 1M arrays). “Escaped” cells 
acquired chromosomal aberrations, in the form of gains and losses that ranged in size from 
approximately 1.26Kb to 48Mb. 
 
Supplementary Table 12. Results from cytogenetic analysis in “escaped” (ON) Saos2 
p21WAF1/Cip1 cells depict the predominance of breakpoints of random re-arrangements in 
Fragile Sites (FSs). 
 
Supplementary Table13. Chromosomal coordinates of breakpoints found by deep 
sequencing in Saos2 p21WAF1/Cip1 Tet-ON. 
 
Supplementary Table 14. Chromosomal coordinates of breakpoints found by deep 
sequencing in Li-Fraumeni p21WAF1/Cip1 Tet-ON. 
 
Supplementary Table 15. Shared breakpoints found in the Saos2 p21WAF1/Cip1 Tet-ON 
(from Table 13) and Li-Fraumeni p21WAF1/Cip1 Tet-ON (from Table 14), respectively. 
 
Supplementary Table 16. Breakpoints with microhomologies (MHs) in Saos2 
p21WAF1/Cip1 Tet-ON (69% of total breakpoints) and Li-Fraumeni p21WAF1/Cip1 Tet-On (~71-
80% of total breakpoints) escaped cells. (red line denotes position of breakpoint)  
 
Supplementary Table 17. Molecules displaying up-regulation in Saos2 p21WAF1/Cip1 Tet-
ON escaped cells, stemness abilities and proposed to promote carcinogenesis. 
 
Supplementary Table 18. Molecules displaying up-regulation in Saos2 p21WAF1/Cip1 Tet-
ON escaped cells and proposed to promote carcinogenesis. 
 
Supplementary Table 19. Molecules found expressed in Saos2 p21WAF1/Cip1 Tet-ON 
escaped cells and proposed to display a bimodality in cancer promotion. 
 
Supplementary Table 20. Molecules displaying up-regulation in Li-Fraumeni 
p21WAF1/Cip1 Tet-ON escaped cells, stemness abilities and proposed to promote 
carcinogenesis. 
 
Supplementary Table 21. Molecules displaying down-regulation in Li-Fraumeni 
p21WAF1/Cip1 Tet-ON escaped cells. 
 
Supplementary Table 22. Molecules found expressed in Li-Fraumeni p21WAF1/Cip1 Tet-
ON escaped cells and proposed to display a bimodality in cancer promotion. 
 
Supplementary Table 23. List of antibodies employed in immunohistochemistry, 
immunofluorescence, immunoblotting, immunoprecipitation and chromatin. 
 
Supplementary Table 24. Primers and annealing temperatures used in real time (RT)-
PCR and ChIP analyses. 
 
Supplementary Table 25. Statistics Source Data. 
 
 
 
 
 
Supplementary Video legends 
 
Supplementary Video 1. Dividing Saos2 p21WAF1/Cip1 Tet-OFF cells. 
 
 
Supplementary Video 2. Senescent Saos2 p21WAF1/Cip1 Tet-ON cells. 
 
 
Supplementary Video 3. Senescent and dying Saos2 p21WAF1/Cip1 Tet-ON cells. 
 
 
Supplementary Video 4. Re-replicating Saos2 p21WAF1/Cip1 Tet-ON cells. 
 
 
Supplementary Video 5. Escaped and diving Saos2 p21WAF1/Cip1 Tet-ON cells. 
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Concordance between aCGH and NGS analyses in Saos2 p21WAF1 Tet-ON cells 
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Concordance between aCGH and NGS analyses in Li-Fraumeni p21WAF1 Tet-ON cells 
175 breakpoints – 1st replicate (102 fragile sites) 
breakpoints with microhomologies: 120 (68.57%) 
152 breakpoints – 2nd replicate (78 fragile sites) 
breakpoints with microhomologies: 105 (69.08%) 
71 common breakpoints (40 fragile sites) 
breakpoints with microhomologies: 50 (70.42%) 
a.  Saos2 p21WAF1 Tet-ON 
breakpoints with 
microhomologies ≥ 4 bp 
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Chromosome 16→7 
Chromosome 6→15 
44 breakpoints – 1st replicate (24 fragile sites) 
breakpoints with microhomologies: 35 (79.55%) 
34 breakpoints – 2nd replicate (19 fragile sites) 
breakpoints with microhomologies: 24 (70.59%) 
9 common breakpoints (4 fragile sites) 
breakpoints with microhomologies: 7 (77.77%) 
b. 
Li-Fraumeni p21WAF1 Tet-ON 
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microhomologies ≥ 3 bp 
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